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ABSTRACT 
 
The purpose of this study was to determine if a buffered creatine monohydrate 
(KA) that has been purported to promote greater creatine retention and training 
adaptations with fewer side effects at lower doses is more efficacious than creatine 
monohydrate (CrM) supplementation in resistance-trained individuals.    
In a double-blind manner, 36 resistance-trained participants (20.2±2 years, 181±7 
cm, 82.1±12 kg, and 14.7±5 % body fat) were randomly assigned to supplement their 
diet with CrM or KA at two different dosages.  Muscle biopsies from the vastus lateralis, 
fasting blood samples, body weight, DEXA determined body composition, and Wingate 
Anaerobic Capacity (WAC) tests were performed at 0, 7, and 28-days while 1RM 
strength tests were performed at 0 and 28-days.   Data were analyzed by a repeated 
measures multivariate analysis of variance (MANOVA) and are presented as mean ± SD 
changes from baseline after 7 and 28-days, respectively.    
Muscle free creatine content obtained in a subgroup of 25 participants increased 
in all groups over time (p=0.03) after 7 and 28-days, respectively, with no significant 
differences among groups (p=0.46).  Although some significant time effects were 
observed, no significant group x time interactions (p>0.05) were observed in changes in 
body mass, fat free mass, fat mass, percent body fat, or total body water; bench press and 
leg press 1RM strength; WAC mean power, peak power, or total work; serum blood 
lipids, markers of catabolism and bone status, and serum electrolyte status; or, whole 
blood markers of lymphocytes and red cells.   Neither manufacturers recommended 
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doses (1.5 g/d) or KA with equivalent loading (20 g/d for 7-days) and maintenance doses 
(5 g/d for 21-days) of CrM promoted greater changes in muscle creatine content, body 
composition, strength, or anaerobic capacity than CrM (20 g/d for 7-days, 5 g/d for 21-
days).  There was no evidence that supplementing the diet with a buffered form of 
creatine resulted in fewer side effects than CrM.  These findings do not support claims 
that consuming a buffered form of creatine is a more efficacious and/or safer form of 
creatine to consume than creatine monohydrate.   
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CHAPTER I 
INTRODUCTION AND RATIONALE  
Background 
 Creatine is a amino acid-like compound that is involved in the transfer of high 
energy phosphates within the body[1].   There is strong evidence to support the use of 
creatine as an ergogenic aid, especially for those involved in high-intensity exercise such 
as sprinting and weight lifting [2-4].   Creatine supplementation is becoming more and 
more popular not only in athletes but in the recreationally active as well. Recent studies 
estimate that 28-41% of NCAA athletes and 29-57% of recreationally active individuals 
supplement with creatine [5, 6].  The form of creatine that has been most extensively 
studied has been creatine monohydrate (CrM) [2].  There are numerous different 
formulations and combinations of creatine on the market but several studies have 
indicated that creatine monohydrate seems to be the most effective in terms of increasing 
the amount of creatine stored within the body and improving performance [2, 7-11].  
Research has indicated that creatine monohydrate supplementation can increase creatine 
and phosphocreatine concentrations by approximately 15-40% [8, 12-14].   These 
increases in creatine concentrations often times correlate to improvements in 
performance, particularly anaerobic exercise capacity, and increases in training volume 
which can lead to greater gains in strength, power, and muscle mass [2-4, 14-20].  
Creatine supplementation has repeatedly been shown to be safe with minimal side 
effects even following long-term supplementation protocols of 3-5 years[21-27].   A 
number of potential therapeutic benefits have also been suggested in various clinical 
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populations [28-34].  Again, research has continuously shown creatine monohydrate to 
be the most efficacious form of creatine because of its high bioavailability.  For 
example, research suggests that 99% of ingested creatine monohydrate is either taken up 
by tissues or extracted in urine despite allegations of creatine monohydrate being 
degraded to creatinine in the stomach [35-37].  Regardless, supplement manufacturers 
continue to create new formulations of creatine with the intent of creating a more 
efficacious form of creatine.  These newer forms have been purported to have better 
physical and chemical properties, bioavailability, efficacy, and/or safety profiles than 
creatine monohydrate [2].  For example, a company out of Montana has recently created 
a buffered form of creatine (Kre-Alkalyn® [KA], All American Pharmaceutical, Billings, 
MT, USA) that is marketed as a more potent form of creatine and purported to be more 
chemically stable when compared to creatine monohydrate [38].    The company claims 
their product doesn’t degrade to creatinine in the stomach as much as creatine 
monohydrate because it’s buffered and  therefore a lower dosage is required to yield 
similar results [38, 39].   As mentioned previously, research indicates that 99% of 
ingested creatine monohydrate is either taken up by the tissues or excreted in the urine.  
Therefore it is unlikely that Kre-Alkalyn is a “more potent” form of creatine.  In fact, 
researchers have shown the conversion of creatine to creatinine at a pH of 1.0 was less 
than 1% after 5, 30 and 120 minutes while KA had a 35% higher conversion to 
creatinine under similar conditions [40].   
 Creatine monohydrate has continually been shown to be effective with little to no 
side-effects and no detrimental effects on markers of clinical health.  Regardless, KA 
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manufacturers again make claims that their product has less negative side-effects and is 
safer than creatine monohydrate[39].  We therefore designed a study to compare this 
new formulation of creatine to the well-researched, creatine monohydrate.  There were 
two different dosages of KA used in the study, a high (creatine monohydrate equivalent) 
and low (manufacturer’s recommended) dose.  The study utilized a double blind, 
randomized design with 3 groups: 1) A creatine monohydrate group, 2) A recommended 
dose of KA group, and 3) A creatine monohydrate equivalent KA group.  This design 
allowed us to determine the safety and efficacy of this new formulation of creatine. The 
supplementation period consisted of 28-days with the creatine monohydrate and KA 
equivalent groups consuming loading doses (20 g/d) during the first 7-days, followed by 
maintenance doses of 5 g/d for the remaining 21-days and the KA recommended dosage 
group (1.5 g/d) maintained that dose throughout the duration of the study.  This design 
allowed us to assess the acute and long-term effects of the two forms of creatine on 
muscle creatine retention, body composition, strength, anaerobic capacity and markers of 
health status.  If KA was more efficacious than CrM, the recommended dose of 1.5 g/d 
should have been just as, if not more, effective than the creatine monohydrate dosage.  
Additionally, if in fact KA was a more potent form of creatine, ingesting the creatine 
equivalent loading and maintenance doses of KA would’ve theoretically promoted 
greater effects with fewer side effects than those ingesting standard loading and 
maintenance doses of CrM.  It is possible that new formulations of creatine may be more 
efficacious than creatine monohydrate but they must first be investigated in a controlled 
setting to monitor its effectiveness and safety before these types of claims can be made.   
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Specific Aim 
 
Was supplementation with Kre-Alkalyn (a buffered form of creatine) more 
efficacious than creatine monohydrate in terms of increasing creatine availability, 
retention and/or training adaptations compared to creatine monohydrate? 
Purpose of the Study 
 
The purpose of this study was to compare the effects of different forms of 
creatine on creatine availability, retention and training adaptations. 
General Study Overview 
 
This study was a double-blind 28-day supplementation study that compared the 
effects Kre-Alkalyn ® and creatine monohydrate on creatine availability, retention and 
training adaptations.  To contrast the effects of a new form of creatine, Kre-Alkalyn, 
creatine monohydrate was used as a control.  Creatine Monohydrate (CM) is well 
accepted in the literature to be the gold standard of creatine and a successful ergogenic 
aid.  Subjects were randomly assigned to one of 3 groups: 1) Creatine Monohydrate; 2) 
Kre-Alkalyn: equivalent dose to CM; or 3) Kre-Alkalyn: manufacturer’s recommended 
dose.  All three groups returned to the lab for a total of three testing sessions on Days 0, 
7 and 28. Assessment of muscle phosphagen levels, markers of clinical health, body 
composition, body water and anaerobic capacity were measured during each testing 
session while upper and lower body maximal strength were only assessed on Days 0 and 
28.   
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Hypotheses 
The central hypotheses were: 
Ho1:   There will be a significant difference between groups in phosphagen 
levels as measured by muscle biopsies after 7 and 28 days of 
supplementation. 
Ho2:  There will be no significant difference between groups in markers of 
clinical health and safety after 7 and 28 days of supplementation. 
Ho3: There will be no significant difference between groups in body 
composition as measured by dual x-ray absorptiometry (DEXA) after 7 
and 28 days of supplementation. 
Ho4: There will be a significant difference between groups in anaerobic 
capacity as measured by the 30 second Wingate test on a Lode cycle 
ergometer after 7 and 28 days of supplementation. 
Ho5: There will be no significant difference between groups in strength as 
measured by 1RM on the leg press and bench press exercises after 28 
days of supplementation. 
Delimitations 
This study was conducted under the following guidelines: 
1. Thirty-six (n = 36) resistance trained males age 18-40 were recruited for this 
study.   
2. Subjects refrained from the consumption of dietary supplements, anabolic 
steroids, and/or ergogenic aids (excluding daily vitamins and protein 
supplements) for at least three months prior to initiating testing. 
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3. Eligible participants took part in a familiarization session during which time they 
were informed of the study protocol, filled out necessary paperwork including an 
informed consent form, performed a trial anaerobic capacity test and were 
scheduled for testing. 
4. Subjects completed a 4 day dietary record prior to each testing session and were 
advised to maintain a consistent diet throughout the duration of the study. 
5. Subjects were advised to maintain a consistent workout regimen throughout the 
duration of the study and recorded all workouts in a workout log. 
6. Muscle biopsies were obtained from the vastus lateralis at each testing session 
which were analyzed for muscle creatine content. 
7. Subjects refrained from strenuous exercise at least 48 hours prior to each testing 
session. 
8. Subjects were fasted for at least 8 hours prior to each testing session. 
9. Subjects performed to their maximal ability on all strength and anaerobic 
capacity tests. 
10. Subjects were instructed to consume all supplements, record times of 
consumption and report any side effects in a daily supplement log.   
Limitations 
 
1. The participants were individuals from the Texas A & M community and 
surrounding fitness facilities that responded to recruitment fliers and emails; 
therefore the selection process was not truly random. 
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2. While there were some variations in testing times and dietary intake, all efforts 
were made to conduct testing sessions at the same approximate time to account 
for diurnal variations and subjects were instructed to maintain a consistent diet 
throughout the duration of the study. 
3. Motivations and effort during performance testing may not have been 100% at 
each testing session. 
4. Subjects may not have followed the supplement instructions. 
5. All participants were instructed to maintain a consistent training program and 
keep a workout log.  However, exercise habits during the duration of the study 
may have changed and therefore changes in performance measures may have 
been influenced by the training program rather than the assigned supplement.  
6. All equipment was calibrated according to manufacturer guidelines and all 
samples were run in duplicate to reduce likelihood of error.  However, there are 
innate limitations of the laboratory equipment that were used for data collection 
and analysis.   
Assumptions 
 
1. Participants followed the protocol that was explained to them during the 
familiarization session. 
2. Participants answered the entrance questionnaires accurately and honestly prior 
to being accepted into the study. 
3. Participants adhered to the supplementation protocol and testing schedule. 
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4. All laboratory equipment was calibrated and functioning properly prior to all 
testing sessions. 
5. The population, which the sample was drawn from, was normally distributed. 
6. The variance among the population sample was approximately equal. 
7. The sample was randomly assigned to the different supplement groups. 
8. Participants maintained a consistent dietary intake and exercise regimen 
throughout the duration of the study. 
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CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
Creatine (N-(aminoiminomethyl)-N-methyl glycine) has become one of the most 
popular nutritional supplements on the market [2].  It’s estimated that nearly 15 to 30% 
of high school athletes and 48% of male division I college athletes supplement with 
creatine [41-43].  Creatine, also known as methyl guanidine-acetic,  is classified as a 
nitrogen containing organic acid and has a molecular formula of C4H9N3O2 [1].  It is 
produced naturally within the body and is located in brain, liver, kidney and muscle 
tissue with the majority (95%) being located within skeletal muscle [1].  Roughly 60%  
of muscle creatine is in the phosphorylated form, phosphocreatine (PCr)  with the 
remaining 40% being free creatine [21]. An adult male weighing 70 kg has an average of 
100-150 g of total body creatine [1].  The human body is able to synthesize roughly 2 
g/day with the remainder of the creatine coming from food sources, specifically meats 
and fish. 
Creatine is essential to life as it plays a vital role in the transfer of energy within 
cells [44]. Energy is provided to the cell through the hydrolysis of adenosine 
triphosphate (ATP) to adenosine diphosphate (ADP) and inorganic phosphate (Pi). 
Through a reversible action involving phosphocreatine (PCr), ADP, hydrogen ions (H+) 
and the enzyme creatine kinase (CK), ATP can be rapidly resynthesized when the 
phosphate group from PCr is added to ADP resulting in ATP and creatine. This reaction 
helps to maintain intracellular ATP availability and acts as a buffer for H+ [1].  Creatine 
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may also assist with the transfer of high energy phosphates from the mitochondria to 
areas of ATP utilization via the creatine phosphate shuttle[45]. 
ATP is rapidly degraded during high intensity exercise in order to provide energy 
for the contractile proteins within skeletal muscle. Muscle phosphagens are involved in 
the replenishment of ATP during exercise.  Phosphocreatine has been proposed as one of 
the limiting factors to muscle performance; especially during short bouts of high 
intensity exercise [1].  There is evidence that suggests PCr is the first and most 
prominent fuel source used to resynthesize ATP during high-intensity exercise[45].  
Previous research has shown that the rate of PCr resynthesis after high intensity exercise 
is positively correlated with exercise performance during a subsequent bout of high 
intensity exercise [46, 47].  Therefore by increasing pre-exercise levels of PCr as well as 
post-exercise rates of PCr resynthesis, improvements in muscle contractile capacity 
would likely follow due to an enhancement in the shuttling of high-energy phosphates 
via the creatine phosphate shuttle.  A way to increase PCr stores is to supplement the diet 
with exogenous creatine with the intention of increasing the potential for creatine 
transport into the musculature. 
Effects of Creatine Supplementation on Phosphagen Levels 
 The human body is able to synthesize roughly 2 g of creatine per day from the 
amino acids glycine, arginine, and methionine[48].  Also, 1-2% of the creatine pool is 
broken down in to creatinine and excreted through the urine each day  as part of normal 
daily turnover [21].   Therefore, the creatine content within the body at any given time is 
a reflection of the balance between endogenous creatine production, the amount of 
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creatine consumed in the diet and the amount of creatine degraded each day. If enough 
creatine is not taken in through the diet, creatine supplementation may be necessary to 
maintain adequate levels.  Several supplementation strategies have been implemented 
with the intent of increasing phosphagen levels within the muscle and ultimately 
improving performance. The increases seen in muscle creatine stores following 
supplementation strategies appear to be dependent on the amount of creatine ingested, 
duration of the supplementation period and the initial levels of creatine stores prior to 
supplementation [21].  Several researchers have also suggested that there is likely a 
maximal amount of total creatine that can be stored within the body, somewhere in the 
range of 150-160 mmol/kg dm [7, 13, 49]. 
 Creatine research began to gain popularity during the late 1980’s and early 
1990’s.  One of the earlier creatine supplementation studies done by Harris et al. found 
that 20 g of creatine per day, ingested for 5 days, led to a 20% increase in total muscle 
creatine concentration, of which approximately 20% was in the form of PCr [13].  The 
authors also found that creatine uptake was greatest during the first 2 days of 
supplementation, suggesting that rapid increases in muscle creatine content can be seen 
when supplementing with high doses of creatine.  Hultman et al. utilized a similar dosing 
strategy which had subjects following a protocol that involved 20 g/d for 6 days or a 
lower-dose protocol consisting of 3 g/day for 28 days [14].  Similar to the study 
mentioned above, authors observed increases in muscle creatine of approximately20% in 
both groups.  However, the 20 g/day group experienced increases in muscle creatine at a 
much faster rate compared to the lower dose of 3 g/d.  These early studies led to the 
 12 
 
 
development a supplementation strategy that is more commonly known as a “loading 
phase.”  A loading phase is characterized by the consumption of .3g/kg/day (~20g) of 
creatine for a 3-5 day period in order to achieve rapid increases in muscle phosphagen 
levels.  Research has shown loading protocols to increase muscle creatine and PCr stores 
by ~10-40% [21] in as little as 3-5 days[50, 51].  There is also some evidence which 
seems to suggest there is little to no additional benefit of consuming more than 20 g of 
creatine per day [1].  Also during a loading phase, researchers recommend ingesting 5g 
every 4-5 hours (~20 g total) in order to maintain peak creatine plasma levels [13] 
throughout the day.   
Other creatine supplementation strategies, such as “cycling” have been used as 
well.  Cycling protocols consists of multiple “loading” phases of 3-5 days every 3 to 4 
weeks [48, 51].  More modest strategies have also been employed which don’t include 
any loading phase and rather consist of maintenance dosages (3-6 g/d [52]) for extended 
periods of time [53, 54].  These protocols seem to be just as effective as loading 
strategies but increases in creatine stores appear to be more gradual [21].  There does 
seem to be a minimal dose of at least 2 g/d in order to elicit significant increases in 
muscle phosphagen levels [55].  Although the majority of research has shown creatine 
supplementation to be an effective strategy for increasing muscle phosphagen levels, 
some studies have failed to show a significant effect.  For example, Odland et al. failed 
to observe any significant increases in muscle phosphagen levels following 20 g of 
creatine for 3 days [56].  However, the study utilized a crossover design consisting of a 
14 day washout period which may not have been enough time for creatine levels to 
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return back to baseline.  Research suggests that increased creatine levels will likely 
return to baseline around 30 days following the cessation of supplementation [1, 14] 
Effects of Creatine on Measures of Performance 
 Creatine supplementation has been shown to be an effective strategy to improve 
performance in a variety of ways.  There are over a 1,000 published research articles in 
peer-reviewed journals examining the efficacy of creatine supplementation [57].  The 
vast majority of them (~70%) have shown creatine to have some sort of ergogenic value, 
whether it be improved strength, power, muscular endurance or improvements in 
training adaptations.  The average improvement seen in performance typically ranges 
between 10-15% following creatine supplementation [48].  These improvements can 
occur following short-term and long-term supplementation periods and seem to be 
augmented when combined with a structured training program.   
Anaerobic Performance  
The majority of improvements seen in performance are during those activities 
consisting of short-duration, high-intensity bouts of exercise.  The average effect size 
(ES) of creatine supplementation on activities lasting less than 30s is 0.24 ± 0.02[58].  
The average percent change from baseline is 7.5 ± 0.7% for creatine supplementation 
groups compared to 4.3 ± 0.6% for placebo.  According to a meta-analysis that was done 
in 2002, the average increases seen in bench press 1 RM was 6.85 kg and 9.76 kg for 
back squat 1RM in creatine groups when compared to placebo [59]. 
Improvements in performance have been observed in as little as 3-5 days 
following the initiation of creatine supplementation when loading doses are used.  For 
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example, Volek and associates observed greater increases in the amount of work 
completed during 5 sets of bench press and jump squats in a creatine supplementation 
group (25 g/d) compared to placebo after only 7 days of supplementation [60].  Wright 
et al. observed significant improvements in peak power and mean power during 6 sets of 
10 sec sprints on a cycle ergometer following creatine supplementation (20 g/d for 6 
days)[61].  In a similar study, Tarnopalsky et al. reported increases in cycling power 
following creatine supplementation (20 g/d for 4 days)[62].   Furthermore, Urbanski et 
al. observed a significant increase in knee extension strength and time to fatigue 
following creatine supplementation (20 g/d for 5 days).  There have been hundreds of 
other studies done examining the effects of short-term loading strategies on measures of 
anaerobic performance with the majority of them seeing improvements in strength, total 
work done, time to fatigue, and power [17, 21, 48, 51, 57, 63-66] .   Furthermore, 
loading protocols typically lead to increases in body mass of about 1 to 2 kg after only 1 
week of supplementation[57].  Therefore it appears as though loading protocols 
consisting of ~20 g/d for 5-7 days are an effective way to improve performance during 
bouts of short, high-intensity exercise. 
Similar improvements in anaerobic performance are seen when longer duration 
supplementation periods are used.  For example, Kreider et al. found that 28 days of 
creatine supplementation resulted in a significant increases in total work performed 
during 6 s sprints compared to placebo [19].  In a similar study, Kelly et al. found a 
significant improvement in upper body 3RM and total work completed during 5 sets of 
bench press in power lifters following 28-days of creatine supplementation [67]. Similar 
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improvements were seen in body mass and lean body mass in those supplementing with 
creatine. Similarly, Grindstaff et al. found that creatine supplementation ( 21 g/d for 9 
days) significantly improved high-intensity swim performance during 3 x 100m freestyle 
swims with 60 s rest in between sets as well as ergometer performance during 3 x 20s 
sprints with 60 s recovery in between sprints [68]. 
 However, not all evidence suggests improvements in performance following 
creatine supplementation.  For example, Deutekom et al. reported that creatine 
supplementation (20 g/day for 5 days) did not improve maximal exercise performance 
during sprint cycling or improve muscle recovery from electrical stimulation in well-
trained rowers [69].  In a similar study, Febbraio et al. failed to observe increases in 
supramaximal cycling performance following 5 days of creatine loading despite 
increases in creatine content [70].  Similarly, Green et al failed to see improvements in 
mean and peak power during consecutive upper and lower body Wingate tests after six 
days of supplementation (20 g/d) [71].  Barnett et al. failed to observe any improvements 
in cycling power during consecutive bouts of high-intensity cycling sprints following 
creatine loading [72].  Several other studies have failed to show any significant 
improvements in high-intensity exercise performance following creatine 
supplementation [73][74, 75] [76].  Even when supplementation periods are extended 
over time, studies still have failed to show any benefits from creatine.  For example, 
Stout et al. failed to observe improvements in vertical jump performance or 100 yd sprint 
times following 56 days of creatine supplementation (21 g/d for 5 days and 10.5 g /d for 
51 days) during an off-season football training program.  However, it appears as though 
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studies that fail to observe improvements in performance, generally still see a 1-7% 
improvement; albeit not statistically significant [57]. 
Evidence suggests that when creatine is supplemented with a structured training 
program, greater improvements can be seen in muscle creatine content, sprint 
performance, strength, power, lean body mass and rate of force development versus 
those not taking creatine [48].   In a recent review, researchers summarized the latest 
research that investigated the effects of creatine supplementation on muscle strength and 
weightlifting performance following when combined with a resistance training program 
[77].  Researchers observed that the average increase in muscle strength following 
creatine supplementation and resistance training was a 20% compared to only 12% in 
placebo groups. They also concluded that the average increase in muscular endurance or 
weightlifting performance following a resistance training program was 26% for creatine 
and 12% for placebo groups.  There are several other studies that support these findings.  
For example, Noonan et al. found a significant improvement in upper body strength 
when creatine supplementation was combined with an 8 week resistance training 
program [78].  Similarly, Vandenberghe et al. found significant improvements (20-25%) 
in 1RM for leg press, leg extension, squat and arm flexion torque following when 
creatine supplementation was combined with 10 weeks of resistance training in 
previously sedentary females [79]. Furthermore, the creatine group experienced 
significantly greater gains in lean body mass +5.8% (creatine) vs. +3.7% (placebo) or 
+2.6 kgs compared to +1.6 kgs, respectively.  Other studies have indicated similar 
improvements in fat-free mass from groups following a regular resistance training 
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program when combined with creatine supplementation and typically experience 
increases of 2-4 lbs. more of lean body mass compared to placebo groups [21, 66, 78].   
 The majority of research suggests that improvements in anaerobic performance 
are likely attributable to a higher short-term energy supply before the initiation of 
exercise as well as improvements in PCr resynthesis rates [1, 7, 58, 80].  This will 
ultimately delay PCr depletion, helping to sustain force production during not only a 
single bout but during subsequent bouts of high intensity exercise as well.  For example, 
Birch et al. found lower plasma ammonia levels following 3 successive 30 sec bouts of 
maximal effort isokinetic cycling following creatine loading ( 20 g/d for 5 days) [63].  
The authors suggested these results indicate an improvement in ATP resynthesis rates 
and less reliance on the adenlyate kinsase and adenylate deaminase reactions which lead 
to increases in adenosine monophosphate (AMP) and ultimately ammonia levels if the 
reactions occur at a high rate.  Similar studies have found lower levels of hypoxanthine 
during subsequent bouts of high intensity exercise following creatine supplementation 
[17, 81].  Hypoxantine is well accepted as a marker of skeletal muscle adenine 
nucleotide loss during intense exercise [82]. 
At this time it is unknown whether improvements in training adaptations are a 
result of indirect effects, such as an improved ability to resynthesize PCr during exercise 
and ultimately complete more work during a training bout or a more direct effect by 
stimulating certain anabolic pathways.  After 5 days of creatine loading (21 g/d), 
Deldicque et al. found increases in collagen mRNA, glucose transporter 4 and myosin 
heavy chain IIa expression [83].  The authors suggested that the observed increases in 
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gene expression following creatine supplementation may provide an anabolic 
environment which could be further augmented when combined with resistance training.  
Furthermore, Willoughby and colleagues observed increases in creatine kinase, 
myogenin and myogenic regulatory factor 4 (MRF-4) expression when creatine 
supplementation (6 g/d for 12 weeks) was combined with a resistance training program 
[54].  This again would provide an anabolic-like environment for muscle hypertrophy to 
occur and could lead to increases in fat-free mass over time if combined with a 
structured resistance training program.  Similarly, Burke et al. observed a greater 
increase in IGF-1 concentration following an 8-week resistance training program in a 
creatine supplementation group compared to placebo[84].  It has also been proposed that 
because creatine is a large substance, it may lead to an osmotic gradient and pull water in 
to the muscle cell thus increasing intracellular water and body mass [60]. Some 
researchers suggest that this increase in cellular hydration may stimulate protein 
synthesis and explain some of the anabolic effects of creatine supplementation [20, 49, 
60].   
 Increases in training adaptations following creatine supplementation can also be 
further enhanced when creatine is combined with other nutrients.  For example, Cribb et 
al. observed further increases in 1RM, lean body mass and muscle cross sectional area 
when subjects ingested a supplement containing creatine (0.1 g/kg/d) as well as protein 
and carbohydrates (1.5 g/kg/d) during a resistance training program [85].   Burke et al. 
observed significantly greater improvements in lean body mass, bench press 1RM and 
isokinetic strength following 6 weeks of resistance training and creatine + whey protein 
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supplementation compared to just whey protein alone and/or placebo[86].  In a similar 
study, Noonan et al. found significant improvement s in upper body strength, 100 yd 
dash times, and fat-free mass when carbohydrates were added to creatine during 8 weeks 
of resistance and sprint training [78] 
Aerobic Performance 
 Although the rationale behind creatine supplementation is to enhance short-term 
energy stores by increasing phosphagen levels within skeletal muscle, creatine 
supplementation may also improve longer duration aerobic-like performance as well.  
It’s been proposed that creatine supplementation may improve the shuttling of high-
energy phosphates between the cytosol and mitochondria [11].  In a study done by 
Chwalbinska-Monteta et al., investigators observed an increase in lactate threshold in 
elite male endurance rowers following a short-term loading protocol (20 g/d for 5 days) 
[87].  In a similar study done by Preen et al., creatine loading (20 g/day for 5-d) was 
shown to improve exercise performance during 80 min of repeated-sprint exercise in 
active males [50].  The authors suggested that an improved ability to resynthesize PCr as 
a result of creatine loading likely led to the increases in performance.  Nelson et al. 
reported decreases in submaximal heart rate and oxygen uptake as well as an increase in 
ventilatory threshold and time to exhaustion during a maximal exercise test following 7 
days of creatine supplementation (20 g/d) [88].  Researchers also observed lower 
exercise and recovery lactate values during and after a graded exercise test on a cycle 
ergometer in those supplementing with creatine compared to baseline.  Lower lactate 
 20 
 
 
levels during exercise could assist athletes involved in high-intensity interval training 
and improve the anaerobic threshold.  
Conversely, not all evidence suggests that creatine supplementation will improve 
aerobic performance.  Hickner et al. examined the effects of a 28-d creatine 
supplementation protocol (3g/d) on performance during a 2 hour simulated cycling road 
race in male triathletes [89].  Subjects completed a 2 hour simulated cycling road race 
with intermittent sprints before and after supplementation.  Results indicated no 
improvements in sprint time to exhaustion or power output during a post-race sprint 
following supplementation. 
Clinical Safety and Applications of Creatine Supplementation 
 One of the biggest misconceptions regarding creatine is that it is a potentially 
dangerous supplement with various side-effects. It is well accepted that the only 
significant side effect of creatine supplementation is weight gain [21].  Nevertheless, 
there still seems to be several anecdotal claims in the media and sports world that 
creatine is a dangerous supplement that can lead to cramping, gastrointestinal distress, 
and kidney failure.  These claims continue to persist even though the majority of 
research has demonstrated that creatine supplementation is safe with minimal side 
effects.  Even long-term creatine supplementation has been shown to be safe.  Poortman 
et al. has shown no effect of creatine monohydrate supplementation on renal function 
after 5 years of supplementation [90].  Similarly, Kreider et al. monitored markers of 
clinical health in college football players who were supplementing with creatine for a 3 
year period and failed to observe any changes and/or side effects following 
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supplementation [91].  Creatine has also been used in clinical settings as well in order to 
treat certain diseased populations.  For example, Vannas-Sulonen and colleagues 
supplemented gyrate atrophy patients with a low dose of creatine (1.5 g/d) for 5 years 
and did not observe any side effects [92].  Similarly, infants with creatine synthesis 
deficiencies were given a creatine supplement (4 to 8 g/d) for two years without any 
evidence of clinical side-effects [93].   
There is some evidence that suggests creatine may actually be useful as 
therapeutic agent.  Research suggests that creatine supplementation may lower total 
cholesterol levels and/or increase high-density lipoprotein levels [19, 80].  Also, due to 
creatine’s role in proper brain development and functioning, creatine supplementation 
may be an effective treatment for brain-related disorders linked with deficiencies in 
energy metabolism such as Huntington’s Disease and Parkinson’s Disease [94].  Current 
research is focusing on the possibility of creatine supplementation reducing rates of 
atrophy and muscle wasting in certain neuromuscular disorders as well as spinal cord 
injuries [51, 95-98]. 
New Formulations and Combinations of Creatine Supplementation 
The form of creatine that is the most popular and well researched is creatine 
monohydrate [2].  However, there seems to be a constant influx of new products and 
formulations of creatine in hopes to surpass the efficacy of creatine monohydrate.  For 
example, some manufacturers will combine creatine with other substances such as salts 
and phosphates with the intent of augmenting the effects of creatine or enhancing is 
bioavailability. For example, some of the creatine products on the market include 
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creatine + B-hydroxy-Bmethylbutyrate (HMB), creatine + sodium bicarbonate, creatine 
magnesium-chelate, creatine serum or liquid creatine, creatine ethyl ester, and creatine 
phosphate [21].  There have been several comparative studies in which creatine 
monohydrate have been compared to new formulations of creatine in order to examine 
their efficacy, however creatine monohydrate continues to appears to be the most 
efficacious [21].  Some of the research with creatine + HMB shows promise as well as 
those products which include additional macronutrients supplements as mentioned above 
[85, 99-101]. 
Some new formulations have been shown to be as effective when compared to 
creatine monohydrate.  For example, Peeters and colleagues compared the effectiveness 
of creatine phosphate supplementation to creatine monohydrate [102].  Results indicated 
that the groups ingesting creatine monohydrate and creatine phosphate had similar 
significant increases in body weight, lean body mass, and bench press 1RM following 6 
weeks of resistance training and supplementation compared to a placebo control.   
In a related study, researchers examined the effects of 3 different forms of 
creatine on whole body creatine retention, measured by the amount of creatine excreted 
in the urine subtracted from the amount ingested [8].  Subjects ingested 5 g of dextrose, 
5 g of CrM, 5 g of CrM + 18 g of dextrose, or 5 g of an effervescent creatine supplement 
+ 18 g dextrose, four times a day for 3 days.  Following the loading period, creatine 
retention was greatest in the CrM + carbohydrate group however there were no 
significant differences between the CrM and effervescent groups.  These results suggest 
that the addition of carbohydrates to creatine may augment creatine retention. Also, one 
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can take away that an effervescent creatine supplement is just as effective as creatine 
monohydrate in terms of creatine retention.  In a similar study, Kreider et al. investigated 
the effects of consuming a liquid form of CrM compared to powdered form.  Subjects 
consumed either 20 g of CrM, 2.5 g of liquid CrM (recommended dosage) or 20 g of 
liquid CrM (equivalent dose to CrM and 7 times the manufacturer’s recommendations) 
per day for 5 days [11].  Results indicated that creatine monohydrate supplementation 
increased muscle free creatine content by approximately 31% whereas no increases in 
muscle free creatine content were observed following liquid creatine supplementation 
even though 7 times the recommended dose was used. 
Jager et al. examined the effects of three different forms of creatine on plasma 
creatine concentrations [10]. Subjects ingested either creatine monohydrate (CrM), 
tricreatine citrate (TCC), or creatine pyruvate (CPY).  The CPY group actually had a 
higher mean peak concentration and area under the curve compared to the other 2 
groups.  These results suggest that creatine pyruvate may have a higher bioavailability 
compared to creatine monohydrate.  The authors did mention that muscle biopsies are 
needed in order to conclude that the increases in plasma creatine concentrations 
observed directly correlate to an increase in creatine uptake at the muscle and thus 
increasing skeletal muscle creatine content over time. 
Adding certain macronutrients with creatine has also been shown to improve 
creatine retention.  Researchers have suggested a synergistic effect when carbohydrates 
are ingested with creatine [8, 101].  Green et. al observed a 60%  increase in muscle 
creatine stores when 96g of carbohydrates were combined with 5 g of creatine 
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monohydrate compared to those ingesting solely creatine [101].   The authors suggested 
that the ingested carbohydrates yielded a rise in insulin levels which likely increased the 
transport of creatine into the muscles.  Furthermore, the authors observed a 50% 
reduction in urinary creatine levels when carbohydrates were combined with creatine, 
suggesting an increase in creatine retention.  In a similar study, Steenge and associates 
found that 47g of carbohydrate and 50g of protein was just as effective in improving 
creatine retention as 96g of carbohydrates [103]. The addition of D-pinitol (a plant 
extract with insulin like properties) has also been shown to augment creatine retention 
[104].  This research suggests that creatine bioavailability and retention can be improved 
through the addition of certain macronutrients to a creatine supplement. 
One research group has recently proposed that a buffered form of creatine may 
have a higher bioavailability compared to creatine monohydrate [39].  This group 
suggests that a buffered form of creatine won’t degrade to creatinine in the acidic 
environment of the stomach as rapidly as creatine monohydrate [38, 105].   However 
research has shown that creatine monohydrate is not degraded during normal digestion 
and nearly 99% of orally ingested creatine is either taken up by tissues or excreted in the 
urine [35-37].  In fact, in a recent review, authors described that the degradation of 
creatine can actually be reduced by either lowering the pH to under 2.5, as is seen in the 
stomach, or increasing the pH [2].   Therefore in a very acidic environment, creatine may 
in fact be more stable.  
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Practical Applications 
 From a practical standpoint, creatine supplementation has been shown to be an 
effective method of increasing phosphagen levels within the body.  This increase in 
intramuscular phosphagen levels may improve the ability to resynthesize 
phosphocreatine and sustain a high level of exercise intensity before the onset of fatigue.  
The majority of research has shown creatine to be an effective ergogenic aid with 
significant improvements seen during high-intensity exercise.  Creatine supplementation 
can also augment training adaptations when used together with a structured training 
program.  Creatine supplementation has repeatedly been shown to be safe with minimal, 
if any, negative side-effects.  Creatine monohydrate seems to be the most effective form 
of creatine however it is still important to investigate new formulations as they are 
developed to ensure the efficacy and safety of these new products. 
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CHAPTER III 
METHODS 
Experimental Design 
 Table 1 presents the experimental design of the study and what was required by 
participants during each testing session throughout the 28-days.   The study was 
conducted in a double-blind, match controlled manner utilizing three treatment groups.  
Subjects who qualified for the study participated in a familiarization session during 
which the study protocol and design was explained to the participants.  During the 
familiarization session, informed consent was obtained.  After the familiarization 
session, subjects were matched for bodyweight, years of training experience, and age 
and randomly assigned to one of three groups: 1.) KA at manufacturer’s recommended 
doses (KA-L); 2.) KA at creatine monohydrate equivalent dose (KA-H); or 3) CrM).   
Dietary intake was not controlled but participant’s dietary intake was recorded prior to 
each testing session and analyzed for energy intake and macronutrient content.  
Participants were instructed to maintain their normal resistance-training program and 
maintain training logs so training volume could be compared.   
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Table 1.  Experimental Design 
 
 
Independent and Dependent Variables 
The independent variable of interest was the type of creatine ingested.  
Dependent variables included muscle creatine content, body composition, one repetition 
maximum (1RM) for bench press and leg press, anaerobic sprint performance capacity, 
serum and whole blood clinical markers of health, and self-reported side effects.   
 
 
Familiarization 
and Entry 
Baseline 
Day 0 
Loading Phase 
Day 7 
Maintenance 
Phase 
Day 28 
 
Familiarization session 
Informed Consent Form 
Demographic Form 
Health History Form 
Exercise History Form 
4-day Dietary History 
General Exam to 
Determine 
Qualifications to 
Participate in Study 
Height and Body Weight 
Practice Wingate 
Anaerobic Capacity Test 
Randomization into one 
of three groups (CrM, 
KA-L, KA-H)  
Instructions for 
Supplementation  
 
  
4-Day Diet History 
Muscle Biopsy  
Fasting Blood 
Sample 
Body Weight  
Body Water (BIA) 
DEXA Body 
Composition 
1 RM Leg Press 
1 RM Bench Press 
Wingate Anaerobic 
Capacity Test 
Loading Phase of 
Supplementation 
Begins 
Maintain Training 
Log 
 
 
4-Day Diet History 
Submit Training Log 
Muscle Biopsy  
Fasting Blood 
Sample 
Body Weight  
Body Water (BIA) 
DEXA Body 
Composition 
Wingate Anaerobic 
Capacity Test 
Low-Dose 
Maintenance Phase 
of Supplementation 
Begins 
 
 
 
4-Day Diet 
History 
Submit 
Training Log 
Muscle 
Biopsy  
Fasting Blood 
Sample 
Body Weight  
Body Water 
(BIA) 
DEXA Body 
Composition 
1 RM Leg 
Press 
1 RM Bench 
Press 
Wingate 
Anaerobic 
Capacity Test 
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Study Site 
 All laboratory testing was conducted in the Exercise & Sports Nutrition 
Laboratory with the exception of the muscle biopsies procedures which were performed 
in the Human Countermeasures Laboratory.  Both laboratories were located in the 
Department of Health and Kinesiology at Texas A&M University in College Station, 
TX. 
Subjects 
Thirty-six apparently healthy college aged resistance-trained males were 
recruited to participate in this study.  Participants were not allowed to participate in this 
study if they had any metabolic disorder including known electrolyte abnormalities; 
heart disease, arrhythmias, diabetes, thyroid disease, or hypogonadism; a history of 
hypertension, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; if they 
were taking thyroid, anti-hyperlipidemic, hypoglycemic, anti-hypertensive, anti-
inflammatory, or androgenic medications.  Participants were not allowed to participate if 
they had taken any nutritional supplements or ergogenic aids (i.e. creatine, beta-alanine, 
HMB, DHEA, thermogenics etc) other than a daily multivitamin and protein powder 
within the previous three months.  Participants were recruited from the student 
population and from area fitness facilities.  Recruitment fliers were posted around the 
Health & Kinesiology building as well as emailed to students enrolled in physical 
education activity classes.   Participants meeting entrance criteria were asked to attend a 
familiarization session during which they signed an informed consent form in 
compliance with the Human Subjects Guidelines of the Texas A&M University and the 
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American College of Sports Medicine. 
Familiarization 
 
Prior to the initiation of the study, subjects attended a familiarization session 
during which details of their participation were explained.   This included details of the 
supplementation and exercise protocols, an explanation of how to record dietary and 
exercise information, and a thorough description of the muscle biopsy procedures.  
During familiarization participants completed demographic, health history and exercise 
history forms to ensure they qualified for the study.  Those who met eligibility criteria 
were again informed of the requirements of the study and signed informed consent 
statements in compliance with the Human Subjects Guidelines of Texas A&M 
University and the American College of Sports Medicine.  Participants were also 
weighed using a standard scale and familiarized themselves with the Wingate anaerobic 
capacity test in order to minimize any learning effects.  They were also given further 
instruction on the importance of continuing their regular dietary and exercise routines in 
order to maintain consistency throughout the study.   
Testing Sessions 
  Participants were asked to fast for 8 hours and abstain from exercise 48 hours 
prior to all testing sessions.  Subjects handed in their dietary and exercise logs as well as 
their supplement bags and supplement check sheet (on Days 7 and 28) upon arrival for 
their testing session.  Once reporting to the ESNL lab, subjects were shuttled to the 
Human Countermeasures Lab and donated a muscle biopsy.  Immediately following the 
biopsy, subjects were transferred back to the ESNL and donated a fasting blood sample 
 30 
 
 
using standard clinical procedures.  Subjects were then weighed, and had body water 
assessed using a bioelectrical impedance analyzer (BIA).  Following this test, subjects 
had their body composition assessed using a Dual-Energy X-Ray Absorptiometer 
(DEXA).   
Following the resting tests, subjects completed 1RM tests on the bench press and 
hip sled/leg press (on Days 0 and 28 only) and performed a 30-second Wingate 
anaerobic capacity sprint test on a cycle ergometer at each testing session.  Following 
baseline testing, subjects began a 7-day initial supplementation phase.   After 7 days, 
subjects repeated all tests with the exception of the1RM strength measures.  The subjects 
then followed the maintenance supplementation schedules for 21-days and then returned 
to the lab and completed all tests.  This allowed for the assessment of acute and chronic 
supplementation protocols on muscle creatine levels, body composition, exercise 
performance, as well as markers of clinical health and safety.  Participants were asked to 
maintain their current training programs and record all workouts throughout the 28-day 
period.  Participants were asked to report side effects on a daily basis and record the 
ingestion of all supplements. 
Supplementation Protocol 
 
Following baseline testing, participants were matched according to body weight, 
training status/experience, and age and randomly assigned to one of three groups.  
Depending on which group they were in, subjects ingested, in a double blind manner, 
capsules containing CrM (Creapure® AlzChem AG, Trostberg, Germany, Lot #108631) 
or KA (Kre-Alkalyn® All American Pharmaceutical, Billings, MT, USA, Lot #1067000) 
 31 
 
 
at two different dosages for a 28-day period.  The supplementation protocol that was 
implemented was one that had been shown to be successful in previous creatine 
supplementation studies [19, 89, 106].   Supplements were provided by the supporting 
sponsor in red 0.75 gram (00 sized) capsules and were counted and pre-packaged by an 
individual outside of the research team.  The creatine content of the capsules was 
independently verified by Covance Laboratories Inc. (Madison, WI) and certificate of 
analysis results are presented in Table 2.  Capsules were pre-counted and placed into 
single serving bags which were then placed in another bag to separate the supplements 
by day.  Each daily bag consisted of the single serving bags in order to insure proper 
supplementation throughout the week.  The supplements were then placed in a non-clear 
bag labeled with the participants’ study identification number in a double-blind manner.  
Participants in the CrM group ingested 8 capsules per serving, containing approximately 
5 g of CrM four times daily (20 g/d total) for the first 7-days of the study.  On Day 8 the 
CrM group began their maintenance dose and consumed 8 pills once per day (5 g/d) for 
the remaining 21-days.  A small amount of dextrose (~60 mg pre capsule) was added to 
the CrM supplement to enhance flowability during encapsulation.  Participants in the KA 
creatine monohydrate equivalent group (KA-H) ingested 8 capsules per serving with 
each serving containing approximately 5 g of KA.  The participants ingested this dose 
four times daily (20 g/d) for the first 7-days and then once per day (5 g/d) for the 
remaining 21-days.  Participants assigned to ingest the manufacturers recommended 
doses of KA (KA-L) ingested 8 capsules containing a total of approximately 1.5 g of KA 
mixed with 3.5 g of dextrose once per day and 8 capsules containing 5 g of dextrose 
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three times per day during the initial 7-day loading period.  For the remaining 21-days, 
participants in the KA-L group ingested 8 capsules per day which contained 1.5 g/d of 
KA mixed with 3.5 g of dextrose.  Participants were instructed to ingest supplements at 
8:00 am, 12:00 pm, 4:00 pm, and 8:00 pm during the initial 7-day supplementation 
period and at 8:00 am during the maintenance phase.   Supplementation compliance was 
monitored by having the subjects return empty containers of the supplements at the end 
of each week.  In addition, subjects’ compliance was verified by administering and 
collecting weekly questionnaires.  After completing the compliance procedures, the 
subjects were given the required supplements for the subsequent week. 
 
Table 2.  Supplement Certificate of Analysis Results 
Group Entity 
Weight  
(g) 
Fill 
Weight  
(g) 
Moisture  
(%) 
Creatine 
Monohydrate  
(%) 
Total Creatine 
Monohydrate 
(g/per 8 
capsules) 
Creatinine 
(ppm) 
KA-L 0.7609 0.6375 8.2 30.6 1.56 <5,000 
KA-H 0.7566 0.6358 8.8 102.0 5.19 <5,000 
CrM 0.8171 0.6975 9.4 92.4 5.16 <5,000 
Samples analyzed by Covance Laboratory Inc. (Madison, WI).   Sample size was eight 
capsules.   
 
 
Procedures 
Dietary and Training Analysis 
Participants were instructed to maintain their current dietary habits and to keep 
detailed dietary records throughout the 28-day supplementation period.  Prior to each 
testing session, subjects completed a dietary record that included 3 weekdays and 1 
weekend day.  Dietary inventories were analyzed for average energy and macronutrient 
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intake using the Food Processor Nutrition Analysis Software Version 9.1.0 (ESHA 
Nutrition Research, Salem, OR).  After the dietary forms were entered, a registered 
dietician reviewed and signed off on all dietary inventories.  Participants were also 
instructed to maintain their current training regimen and record the number of sets and 
repetitions per exercise performed throughout the study on training logs.  Training 
volume was calculated by multiplying the amount of weight lifted times the number of 
repetitions performed for each set performed per exercise.  Total training volume during 
the study was analyzed by summing all lifts (upper and lower body) to determine if there 
were any differences among groups.       
Body Composition Assessment 
Body composition testing occurred on day 0, 7 and 28 during the study.   Height 
and weight were recorded to the nearest 0.02 kg and 0.01 cm, respectively, using a self-
calibrating digital scale (Cardinal Detecto Scale Model 8430, Webb City, Missouri).  
Body composition was determined using a Hologic Discovery W QDR series DEXA 
system (Hologic Inc., Waltham, MA) equipped with APEX software (APEX Corporation 
Software version 12.1, Pittsburgh, PA).  During this test subjects laid in a supine 
position for approximately six minutes while a low dose x-ray scanned the entire length 
of their body to determine fat mass and lean mass.  Quality control calibration 
procedures were performed on a spine phantom (Hologic-X-CLAIBER Model 
DPA/QDR-1 anthropometric spine phantom) prior to each testing session.  DEXA has 
been validated as an accurate method for body composition assessment  with a high test 
to test reliability[107].  Previous research in our lab, with a similar subject demographic, 
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has yielded mean coefficients of variation for total bone mineral content and total fat 
free/soft tissue mass of 0.31% to 0.45% with a mean intra-class correlation of 0.985 
[108].   Total body water was estimated using an ImpediMed DF50 bioelectrical 
impedance analyzer (ImpediMed, San Diego, CA).   During this test, the subject laid in a 
supine position while four electrodes were placed on the wrist and ankle and the total 
body water was measured.   
Blood and Muscle Biopsies 
Muscle biopsies were obtained  on days 0,7and 28 using a modified Bergstrom 
needle biopsy technique following standard procedures [109] in order to assess muscle 
creatine content.  Biopsy areas were sterilized with alcohol prep pads and an iodine 
solution.  Prior to the incision, the subjects received a subcutaneous lidocaine injection 
followed by an intra-muscular lidocaine injection to numb the area.   The subject then 
lay still for a ten minute period to allow for the lidocaine to take effect.  Incisions were 
then made on the middle portion of the vastus lateralis of the dominant leg at the 
midpoint between the patella and the greater trochanter of the femur at a depth of 1-2 cm 
into the muscle.  A biopsy needle was then inserted into the muscle and a small portion 
of the muscle (50-70 mg) was suctioned into the needle and sliced prior to extraction.   
Similar procedures were followed for the subsequent biopsies and attempts were made to 
obtain samples from approximately the same location (2 cm superior) using the previous 
incision sites.  After removal, adipose tissue was trimmed from the muscle specimens 
which were then immediately frozen in liquid nitrogen and stored at -80C for later 
analysis.  A total of three muscle samples were obtained (Day 0, 7, & 28).  
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  Subjects donated approximately 10 ml of fasting blood using venipuncture 
techniques from an antecubital vein in the forearm according to standard sterile 
procedures.   Whole blood samples were analyzed for complete blood counts with 
platelet differentials using an Abbott Cell Dyn 3500 automated hematology analyzer 
(Abbott Laboratories, Abbott Park, IL).   The remaining whole blood was centrifuged at 
1,500 rpm for 15 minutes in order to separate out the blood components.  Serum blood 
samples were sent to Quest Diagnostics (Houston, TX) for comprehensive metabolic 
panel analysis using an Olympus AAU 5400 Chemistry Immuno Analyzer (Olympus 
America Inc., Center Valley, PA).  If analysis indicated values outside the range for 
clinical norms, samples were run in duplicate.   Previous assays performed in our 
laboratory have yielded a test to test reliability of 2 to 6%.    
Biochemical Analysis for Muscle Creatine 
The muscle tissue samples were analyzed using a mass spectrophotometer for 
muscle creatine (Cr) content.  Samples were analyzed in duplicate for Cr based on 
methods developed by Harris and colleagues [14, 18, 110].  The previously frozen 
muscle tissue samples were placed in a vacuum centrifuge (Savant ISS110 SpeedVac 
Concentrator, Thermo Scientific, Milford, MA) and centrifuged for approximately24 
hours.  Following the dehydration process, the samples were grinded into a power using 
a porcelain mortar and pestle and then placed into pre-weighed microfuge tubes.  The 
first assay used a 0.5 M perchloric acid/ 1mM EDTA solution to extract the muscle 
metabolites.  The solution was added to the microfuge tubes and then placed on ice for 
15 minutes while periodically vortexing.  Samples were then centrifuged at 7,000 rpm 
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for 5 minutes.  The supernatant was transferred into a pre-weighed microfuge tube.  A 
base solution consisting of 2.1 M KHCO3/0.3 M MOPS was used to neutralize the 
samples.  The samples were then centrifuged again at 7,000 rpm for 5 minutes and the 
supernatant was removed and placed into microfuge tubes and frozen at -80C.  
The frozen samples were allowed to thaw at room temperature while periodically 
vortexing.  Extracts were then assayed for Cr in the presence of 50 mM imidazole buffer, 
pH 4.7; 5 mM magnesium chloride; 20 mM potassium chloride; 25 µM 
phosphoenolpyruvate; 200 µM ATP; 45 µM NADH; 1250 U/mL lactate dehydrogenase; 
2000 U/mL pyruvate kinase.  The reagents were premixed and combined prior to 
pipetting.  The assay was then carried out in a standard fluorescence microplate reader 
using 10 µL of sample to 1 mL of reagent. The reactant solution was vortexed and read 
using a fluorometer (Shimadzu RFMini 150, Japan) with an excitation wavelength of 
340 nm and an emission wavelength of 460 nm for baseline absorbance values.  Five μL 
of CK (25 μ/mg) were added to 1 mL of the above buffer and stabilized using 1 mL of 
reagent.  After 10 minutes the plate was read again for post-reaction absorbance values. 
Performance Tests 
One-repetition maximum (1RM) tests were completed for the bench press and 
leg press. Strength tests were performed using a standard isotonic Olympic bench press 
and hip sled/leg press (Nebula Fitness, Versailles, OH) according to standardized 
procedures [111].    Participants followed a standard warm up consisting of 10 
repetitions using 50% of their estimated 1RM for the leg press.  Following warm-up, 
subjects attempted a single repetition using a weight near their estimated 1RM.  Subjects 
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rested for 2-minutes in between 1RM attempts and more weight was added if they felt 
they could lift more.  Subjects attempted to reach their 1RM within 3-5 attempts.  Foot 
positioning and sled height was recorded and standardized between testing sessions.  
After a 4-minute recovery period, bench press 1RM was determined following similar 
procedures as the hip sled/leg press 1RM test.  Hand positioning on the bench press was 
measured and standardized between testing sessions. Previous research in our lab on 
resistance-trained participants have yielded low day to day mean coefficients of variation 
and high reliability for the bench press (1.1%, intra-class r=0.99) and hip sled/leg press 
(0.7%, intra-class r=0.91).  Following the maximal strength procedures, subjects rested 
for roughly 20-minutes and then warmed up on a bicycle ergometer for 3-minutes (70 
rpm @ 1 kg resistance).   Participants then performed a 30-second Wingate sprint 
anaerobic capacity test on a Lode Excalibur Sport 925900 cycle ergometer (Lode BV, 
Groningen, The Netherlands) at a standardized work rate of 7.5 J/kg/rev.  The 
participant was asked to pedal as fast as possible prior to application of the workload and 
sprint at an all-out maximal capacity throughout the 30-second test. Test-to-test 
variability in performing repeated Wingate anaerobic capacity tests in our laboratory 
have yielded correlation coefficients of r=0.98 ±15% for mean power.  Participants 
practiced the anaerobic capacity test during the familiarization session to minimize 
learning effects during which time seat height and pedal position was assessed and 
recorded. 
Side Effect Assessment 
Participants were given weekly questionnaires to determine how well they 
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tolerated the supplement, how well they followed the supplement protocol, and if they 
experienced any medical problems/symptoms as a result of the supplement.  Compliance 
to the supplementation protocol was monitored by having the subjects turn in empty 
weekly supplement containers, supplement logs and verbal confirmation.  After 
completing the compliance procedures, subjects were given the required supplements 
and dosages for the following supplementation period. 
Data Analysis 
 
All data were analyzed using the statistical software SPSS 16.0.  Study data were 
analyzed using a 3 x 3 (group x time) repeated measures Multivariate Analysis of 
Variance (MANOVA). Delta values were calculated and used to determine percent 
changes from baseline which were analyzed by repeated measures ANOVAs to 
determine changes from baseline.  Participant baseline demographic data were analyzed 
using a one-way Analysis of Variance (ANOVA). Overall MANOVA effects were 
examined as well as MANOVA univariate group effects for certain variables if 
significant interactions were seen.  Greenhouse-Geisser univariate tests of within-
subjects time and group x time effects and between-subjects univariate group effects 
were reported for each variable analyzed within the MANOVA model.  Data were 
considered statistically significant when the probability of type I error was 0.05 or less 
and statistical trends were considered when the probability of error ranged between 
p>0.05 to p<0.10.  If a significant group, treatment and/or interaction alpha level was 
observed, Tukey’s least significant differences (LSD) post-hoc analysis was performed 
to determine where significance was obtained.  Prior to initiation of the study, we ran a 
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priori power analysis which indicated a design with an n-size of 12 per group would 
provide sufficient power to identify previously reported changes in muscle creatine 
content and training adaptations in responses to creatine supplementation (>0.70).  
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  CHAPTER IV 
RESULTS 
Introduction 
 Creatine is one of the most popular and effective dietary supplements for 
athletes, specifically those engaged in resistance training [2, 3].  A recent study 
estimated that 28-41% of NCAA athletes and roughly 29-57% of recreationally active 
individuals supplement with creatine [5, 6].  Creatine is an amino acid-like compound 
that is involved in the transfer of high energy phosphates within the body and can yield 
energy at a high rate [2].  The form of creatine that has been most extensively studied is 
creatine monohydrate (CrM) [2].  Research has consistently indicated that 
supplementation with CrM can increase muscle creatine and phosphocreatine stores by 
as much as 10-40%, enhance anaerobic capacity, and enhance training adaptations when 
combined with a structured training program [2, 7, 13, 14, 17, 19].  Furthermore, 
creatine supplementation has repeatedly been shown to be safe with minimal negative 
side-effects, despite several cases of anecdotal evidence in the media reporting 
cramping, dehydration, compartment syndrome etc.   
 Research has shown that CrM has a high bioavailability and that the majority of 
CrM is not degraded during normal digestion, with nearly 99% of orally ingested 
creatine either taken up by the tissues or excreted through the urine [35-37].  
Nevertheless, manufacturers attempt to create new forms of creatine and promote them 
to be more efficacious than CrM.  Recently, manufacturers have created a buffered form 
of creatine (Kre-Alkalyn® [KA], All American Pharmaceutical, Billings, MT, USA )and 
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it has been marketed as a more “potent form of creatine” with “less side-effects than 
creatine monohydrate” [39].  The company claims their product is more chemically 
stable than creatine monohydrate and doesn’t degrade to creatinine in the stomach as 
much as creatine monohydrate because it’s buffered [38].  According to patent filings 
this is possible by the addition of an alkaline powder (e.g., soda ash, magnesium glycerol 
phosphate and bicarbonate) to creatine (e.g., creatine monohydrate, creatine phosphate, 
creatine pyruvate and creatine citrate) [105].  They also claim that because KA does not 
degrade to creatinine in the stomach, that a lower dose is required to yield similar 
increases in creatine content as those seen from CrM supplementation [38].  Even 
though research investigating creatine monohydrate supplementation has continually 
shown CrM to be safe with no negative side-effects, KA manufacturers also claim their 
product is safer.   
The manufacturer cites several clinical studies on their website performed in 
Bulgaria to support their claims however we could not find any peer-review published 
articles on the National Library of Medicine’s PubMed related to “Kre-Alkalyn” or 
“buffered creatine” [38].  We therefore designed a study to compare this new 
formulation of creatine to the well-researched, creatine monohydrate.  Two different 
dosages of KA were used in the study, a high (creatine monohydrate equivalent) and low 
(manufacturer’s recommended) dose.  The study was designed as a double blind match-
controlled design with 3 groups: 1) A recommended dose of KA, 2) A creatine 
equivalent dose of KA group and 3) A creatine monohydrate group.  This design allowed 
us to determine the safety and efficacy of this new formulation of creatine and its effects 
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on creatine retention, training adaptations and markers of clinical health.  The 
supplementation period consisted of 28-days with the creatine monohydrate and KA 
equivalent groups consuming loading doses (20 g/d) during the first 7-days, followed by 
maintenance doses of 5 g/d for the remaining 21-days and the KA recommended dosage 
group (1.5 g/d) will maintain that dose throughout the duration of the study.  This design 
also allowed us to assess the acute and long-term effects of the two forms of creatine. 
Methods 
 The study was conducted in a double-blind, match controlled design.  Table 3 
presents the experimental design of the study and the schedule for testing sessions.  The 
independent variable of interest was the type of creatine ingested.  Dependent variables 
included muscle creatine content, body composition, one repetition maximum (1RM) for 
bench press and leg press, anaerobic sprint performance capacity, serum and whole 
blood clinical markers of health, and self-reported side effects.  Subjects who qualified 
for the study participated in a familiarization session during which the study protocol 
and design was explained to the participants and informed consent was obtained.   After 
the familiarization session, subjects were matched for bodyweight, years of training 
experience, and age and randomly assigned to one of three groups: 1.) KA at 
manufacturer’s recommended doses (KA-L); 2.) KA at creatine monohydrate equivalent 
dose (KA-H); or 3) CrM).   Dietary intake was not controlled but participant’s dietary 
intake was recorded prior to each testing session and analyzed for energy intake and 
macronutrient content.  Participants were instructed to maintain their normal resistance-
training program and maintain training logs so training volume could be compared.  All 
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laboratory testing was conducted in the Exercise & Sports Nutrition Laboratory with the 
exception of the muscle biopsies procedures which will be performed in the Human 
Countermeasures Laboratory at Texas A&M University in College Station, TX. 
 
Table 3.  Experimental Design and Schedule of Testing Sessions 
 
 
 
 
 
 
Familiarization 
and Entry 
Baseline 
Day 0 
Loading Phase 
Day 7 
Maintenance 
Phase 
Day 28 
 
Familiarization session 
Informed Consent 
Form 
Demographic Form 
Health History Form 
Exercise History Form 
4-day Dietary History 
General Exam to 
Determine 
Qualifications to 
Participate in Study 
Height and Body 
Weight 
Practice Wingate 
Anaerobic Capacity 
Test 
Randomization into 
one of three groups 
(CrM, KA-L, KA-H)  
Instructions for 
Supplementation  
 
  
4-Day Diet History 
Muscle Biopsy  
Fasting Blood 
Sample 
Body Weight  
Body Water (BIA) 
DEXA Body 
Composition 
1 RM Leg Press 
1 RM Bench Press 
Wingate Anaerobic 
Capacity Test 
Loading Phase of 
Supplementation 
Begins 
Maintain Training 
Log 
 
 
4-Day Diet History 
Submit Training Log 
Muscle Biopsy  
Fasting Blood Sample 
Body Weight  
Body Water (BIA) 
DEXA Body 
Composition 
Wingate Anaerobic 
Capacity Test 
Low-Dose 
Maintenance Phase of 
Supplementation 
Begins 
 
 
 
4-Day Diet 
History 
Submit Training 
Log 
Muscle Biopsy  
Fasting Blood 
Sample 
Body Weight  
Body Water 
(BIA) 
DEXA Body 
Composition 
1 RM Leg Press 
1 RM Bench 
Press 
Wingate 
Anaerobic 
Capacity Test 
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Subjects 
 
Thirty-six apparently healthy college aged resistance-trained males were 
recruited to participate in this study.  Participants were not allowed to participate in this 
study if they had any metabolic disorder including known electrolyte abnormalities; 
heart disease, arrhythmias, diabetes, thyroid disease, or hypogonadism; a history of 
hypertension, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; if they 
are taking thyroid, anti-hyperlipidemic, hypoglycemic, anti-hypertensive, anti-
inflammatory, or androgenic medications.  Participants were not allowed to participate if 
they had taken any nutritional supplements or ergogenic aids (i.e. creatine, beta-alanine, 
HMB, DHEA, thermogenics etc) other than a daily multivitamin and protein powder 
(protein or amino acids only) within the past three months.  Participants were recruited 
from the student population and from area fitness facilities.  Participants meeting 
entrance criteria were asked to attend a familiarization session during which details of 
their participation were explained and they signed an informed consent form in 
compliance with the Human Subjects Guidelines of the Texas A&M University and the 
American College of Sports Medicine.  Participants were also weighed using a standard 
scale and familiarized themselves with the Wingate anaerobic capacity test in order to 
minimize any learning effects.   Figure 1 represents a consort diagram for participation 
throughout the study. 
 
 
 
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Testing Sessions 
  Participants were asked to fast for 8 hours and abstain from exercise for 48 hours 
prior to all testing sessions.  Subjects handed in their dietary and exercise logs as well as 
their supplement bags and supplement check sheet (on Days 7 and 28) upon arrival.  
Once reporting to the ESNL lab, subjects donated a muscle biopsy.  Following the 
muscle biopsy, subjects donated a fasting blood sample using standard clinical 
procedures.  Subjects were then weighed, had body water assessed and body 
composition assessed.   
Following the resting tests, subjects completed 1RM tests on the bench press and 
Withdrawal After 
Commencement 
(n=1)  
Subject became ill 
(unrelated to 
supplementation 
protocol) 
Randomization 
(n=37) 
Allocated to  
KA-H Group  
(n=12) 
Allocated to  
KA-L Group 
(n=13) 
Completed 
Study 
(n=12) 
Completed 
Study 
(n=12) 
Figure 1.  Consort diagram for participation.   
Withdrawal Prior to 
Commencement 
(n=4) 
 
Failed to Complete 
Baseline Testing (due to 
time constraints and 
apprehension of study) 
 
Eligible for participation 
(n=41) 
 
Allocated to  
CrM Group  
(n=12) 
Completed 
Study 
(n=12) 
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hip sled/leg press (on Days 0 and 28 only) and performed a 30-second Wingate 
anaerobic capacity sprint test on a cycle ergometer at each testing session.  Following 
baseline testing, subjects began a 7-day initial supplementation phase.   After 7 days, 
subjects repeated all tests with the exception of the1RM strength measures.  The subjects 
then followed a maintenance supplementation schedule for 21-days and then returned to 
undergo all tests.  This allowed for the assessment of acute and chronic supplementation 
protocols on muscle creatine levels, body composition, exercise performance, as well as 
markers of clinical health and safety.  Participants were asked to maintain their current 
training programs and record all workouts throughout the 28-day period.  Participants 
were also asked to report side effects on a daily basis and record the ingestion of all 
supplements. 
Supplementation Protocol 
 
Following baseline testing, participants were matched according to body weight, 
training status/experience, and age and randomly assigned to one of three groups.  In a 
double blind manner, subjects ingested capsules containing CrM (Creapure® AlzChem 
AG, Trostberg, Germany, Lot #108631) or KA (Kre-Alkalyn® All American 
Pharmaceutical, Billings, MT, USA, Lot #1067000) at two different dosages for a 28-day 
period.  The supplementation protocol that was utilized is one that has been shown to be 
successful in previous creatine supplementation studies [19, 89, 106].   Supplements 
were provided by the supporting sponsor in red 0.75 gram (00 sized) capsules and were 
pre-packaged by an individual outside of the research team.  The creatine content of the 
capsules was independently verified by Covance Laboratories Inc. (Madison, WI) and 
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certificate of analysis results are presented in Table 4.  Each participant received daily 
bags which consisted of single serving bags in order to insure proper supplementation 
throughout the week.  Participants in the CrM group ingested 8 capsules per serving, 
containing approximately 5 g of CrM four times daily (20 g/d total) for the first 7-days 
of the study.  On Day 8 the CrM group then began their maintenance dose and consumed 
8 pills once per day (5 g/d) for the remaining 21-days.  A small amount of dextrose (~60 
mg pre capsule) was added to the CrM supplement to enhance flowability during 
encapsulation.  Participants in the KA creatine monohydrate equivalent group (KA-H) 
ingested 8 capsules per serving with each serving containing approximately 5 g of KA.  
The participant ingested this dose four times daily (20 g/d) for the first 7-days and then 
once per day (5 g/d) for the remaining 21-days.  Participants assigned to ingest the 
manufacturers recommended doses of KA (KA-L) ingested 8 capsules containing a total 
of approximately 1.5 g of KA mixed with 3.5 g of dextrose once per day and 8 capsules 
containing 5 g of dextrose three times per day during the initial 7-day loading period.  
For the remaining 21-days, participants in the KA-L group ingested 8 capsules per day 
which contained 1.5 g/d of KA mixed with 3.5 g of dextrose.  Participants were 
instructed to ingest supplements at 8:00 am, 12:00 pm, 4:00 pm, and 8:00 pm during the 
initial 7-day supplementation period and at 8:00 am during the maintenance phase.   
Supplementation compliance was monitored by having the subjects return empty 
containers of the supplements at the end of each week.  In addition, subjects’ compliance 
was verified by administering and collecting weekly questionnaires.  After completing 
the compliance procedures, the subjects were given the required supplements for the 
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next week. 
 
Table 4.  Supplement Certificate of Analysis 
 
Group Entity 
Weight  
(g) 
Fill 
Weight  
(g) 
Moisture  
(%) 
Creatine 
Monohydrate  
(%) 
Total Creatine 
Monohydrate 
(g/per 8 capsules) 
Creatinine 
(ppm) 
KA-L 0.7609 0.6375 8.2 30.6 1.56 <5,000 
KA-H 0.7566 0.6358 8.8 102.0 5.19 <5,000 
CrM 0.8171 0.6975 9.4 92.4 5.16 <5,000 
Samples analyzed by Covance Laboratory Inc. (Madison, WI).   Sample size was eight 
capsules.   
 
 
Procedures 
Dietary and Training Analysis 
Participants were instructed to maintain their current dietary habits and to keep 
detailed dietary records.  Prior to each testing session, subjects completed a dietary 
record that included 3 weekdays and 1 weekend day.  Dietary inventories were analyzed 
for average energy and macronutrient intake using the Food Processor Nutrition 
Analysis Software Version 9.1.0 (ESHA Nutrition Research, Salem, OR).  After the 
dietary forms were entered, a registered dietician reviewed all dietary inventories.  
Participants were instructed to maintain their current training regimen and record the 
number of sets and repetitions per exercise performed throughout the study on training 
logs.  Training volume was calculated by multiplying the amount of weight lifted times 
the number of repetitions performed for each set performed per exercise.  Total training 
volume during the study was analyzed by summing all lifts (upper and lower body) to 
determine if there are any differences among groups.       
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 Body Composition Assessment 
Body composition testing occurred on days 0, 7 and 28 during the study.   Height 
and weight was recorded to the nearest 0.02 kg and 0.01 cm, respectively, using a self-
calibrating digital scale (Cardinal Detecto Scale Model 8430, Webb City, Missouri).  
Body composition was determined using a Hologic Discovery W QDR series DEXA 
system (Hologic Inc., Waltham, MA) equipped with APEX software (APEX Corporation 
Software version 12.1, Pittsburgh, PA).  DEXA has been validated as an accurate 
method for body composition assessment  with a high test to test reliability[107].  
Previous research in our lab, with a similar subject demographic, has yielded mean 
coefficients of variation for total bone mineral content and total fat free/soft tissue mass 
of 0.31% to 0.45% with a mean intra-class correlation of 0.985 [108].   Total body water 
was estimated using an ImpediMed DF50 bioelectrical impedance analyzer (ImpediMed, 
San Diego, CA).    
Blood and Muscle Biopsies 
Muscle biopsies were obtained  on days 0,7and 28 using a modified Bergstrom 
needle biopsy technique following standard procedures [109] in order to assess muscle 
creatine content.  Incisions were made on the middle portion of the vastus lateralis of the 
dominant leg at the midpoint between the patella and the greater trochanter of the femur 
at a depth of 1-2 cm into the muscle.  A biopsy needle was inserted into the muscle and a 
small portion of the muscle (50-70 mg) was suctioned into the needle and sliced prior to 
extraction.   Similar procedures were made for the subsequent biopsies and attempts 
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were made to obtain samples from approximately the same location (2 cm superior) 
using the previous incision sites.  After removal, adipose tissue was trimmed from the 
muscle specimens which were then immediately frozen in liquid nitrogen and then 
stored at -80C for later analysis.  A total of three muscle samples were obtained (Day 0, 
7, & 28).  
  Subjects then donated approximately 10 ml of fasting blood using venipuncture 
techniques from an antecubital vein in the forearm according to standard sterile 
procedures.   Whole blood samples were analyzed for complete blood counts with 
platelet differentials using an Abbott Cell Dyn 3500 automated hematology analyzer 
(Abbott Laboratories, Abbott Park, IL).   The remaining whole blood was centrifuged at 
1,500 rpm for 15 minutes in order to separate out the blood components.  Serum blood 
samples were sent to Quest Diagnostics (Houston, TX) for comprehensive metabolic 
panel analysis using an Olympus AAU 5400 Chemistry Immuno Analyzer (Olympus 
America Inc., Center Valley, PA).  If analysis indicated values outside the range for 
clinical norms, samples were run in duplicate.   Previous assays performed in our 
laboratory have yielded a test to test reliability of 2 to 6%.    
Biochemical Analysis for Muscle Creatine 
The muscle tissue samples were analyzed using a mass spectrophotometer for 
muscle creatine (Cr) content.  Samples were analyzed in duplicate for Cr based on 
methods developed by Harris and colleagues [14, 18, 110].  The previously frozen 
muscle tissue samples were placed in a vacuum centrifuge (Savant ISS110 SpeedVac 
Concentrator, Thermo Scientific, Milford, MA) and centrifuged for approximately24 
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hours.  Following the dehydration process, the samples were grinded into a power using 
a porcelain mortar and pestle and the placed into pre-weighed microfuge tubes.  The first 
assay used a 0.5 M perchloric acid/ 1mM EDTA solution to extract the muscle 
metabolites.  The solution was added to the microfuge tubes and then placed on ice for 
15 minutes while periodically vortexing.  Samples were then centrifuged at 7,000 rpm 
for 5 minutes.  The supernatant will be transferred into a pre-weighed microfuge tube.  A 
base solution consisting of 2.1 M KHCO3/0.3 M MOPS was used to neutralize the 
samples.  The samples were then centrifuged again at 7,000 rpm for 5 minutes and the 
supernatant was removed and placed into microfuge tubes and frozen at -80C.  
The frozen samples were allowed to thaw at room temperature while periodically 
vortexing.  Extracts were assayed for Cr in the presence of 50 mM imidazole buffer, pH 
4.7; 5 mM magnesium chloride; 20 mM potassium chloride; 25 µM 
phosphoenolpyruvate; 200 µM ATP; 45 µM NADH; 1250 U/mL lactate dehydrogenase; 
2000 U/mL pyruvate kinase.  The reagents were premixed and combined prior to 
pipetting.  The assay was carried out in a standard fluorescence microplate reader using 
10 µL of sample to 1 mL of reagent. The reactant solution was vortexed and read using a 
fluorometer (Shimadzu RFMini 150, Japan) with an excitation wavelength of 340 nm 
and an emission wavelength of 460 nm for baseline absorbance values.  Five μL of CK 
(25 μ/mg) was added to 1 mL of the above buffer and stabilized using 1 mL of reagent.  
After 10 minutes the plate were read again for post-reaction absorbance values. 
Performance Tests 
One-repetition maximum (1RM) tests were completed for the bench press and 
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leg press. Strength tests were performed using a standard isotonic Olympic bench press 
and hip sled/leg press (Nebula Fitness, Versailles, OH) according to standardized 
procedures [111].    Participants followed a standard warm up consisting of 10 
repetitions using 50% of their estimated 1RM for the leg press.  Following warm-up, 
subjects attempted a repetition using a weight equal to their estimated 1RM.  Subjects 
rested for 2-minutes in between 1RM attempts and added more weight if they felt they 
could lift more weight.  Subjects attempted to reach their 1RM within 3-5 attempts.   
Foot positioning and sled height were recorded and standardized between testing 
sessions.  After a 4-minute recovery period, bench press 1RM was determined following 
similar procedures as the hip sled/leg press 1RM test.  Hand positioning on the bench 
press was measured and standardized between testing sessions. Previous research in our 
lab on resistance-trained participants have yielded low day to day mean coefficients of 
variation and high reliability for the bench press (1.1%, intra-class r=0.99) and hip 
sled/leg press (0.7%, intra-class r=0.91).  Following the maximal strength procedures, 
subjects rested for approximately 20-minutes and then completed a warm up on a bicycle 
ergometer for 3-minutes (70 rpm @ 1 kg resistance).   Participants then performed a 30-
second Wingate sprint anaerobic capacity test on a Lode Excalibur Sport 925900 cycle 
ergometer (Lode BV, Groningen, The Netherlands) at a standardized work rate of 7.5 
J/kg/rev.  The participant was asked to pedal as fast as possible prior to application of the 
workload and sprint at an all-out maximal capacity throughout the 30-second test. Test-
to-test variability in performing repeated Wingate anaerobic capacity tests in our 
laboratory have yielded correlation coefficients of r=0.98 ±15% for mean power.  
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Participants practiced the anaerobic capacity test during the familiarization session to 
minimize learning effects during which time seat height and pedal position were 
assessed and recorded. 
Side Effect Assessment 
Participants were given weekly questionnaires to determine how well they 
tolerated the supplement, how well they followed the supplement protocol, and if they 
experienced any medical problems/symptoms as a result of the supplement.  Compliance 
to the supplementation protocol was monitored by having the subjects turn in empty 
weekly supplement containers, supplement logs and verbal confirmation.  After 
completing the compliance procedures, subjects were given the required supplements 
and dosages for the following supplementation period. 
Data Analysis 
 
All data were analyzed using the statistical software SPSS 16.0.  Study data were 
analyzed using a 3 x 3 (group x time) repeated measures A multivariate Analysis of 
Variance (MANOVA). Delta and percent change values were calculated and used to 
determine changes from baseline which were analyzed by repeated measures ANOVAs.  
Participant baseline demographic data were analyzed using a one-way Analysis of 
Variance (ANOVA). Overall MANOVA effects were examined as well as MANOVA 
univariate group effects for certain variables when significant interactions were seen.  
Greenhouse-Geisser univariate tests of within-subjects time and group x time effects and 
between-subjects univariate group effects were reported for each variable analyzed 
within the MANOVA model.  Data were considered statistically significant when the 
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probability of type I error was 0.05 or less and statistical trends were considered when 
the probability of error ranged between p>0.05 to p<0.10.  When a significant group, 
treatment and/or interaction alpha level was observed, Tukey’s least significant 
differences (LSD) post-hoc analysis was performed to determine where significance was 
obtained.  Prior to initiation of the study, we ran a priori power analysis which indicated 
a design with an n-size of 12 per group would provide sufficient power to identify 
previously reported changes in muscle creatine content and training adaptations in 
responses to creatine supplementation (>0.70).  
Results 
Subject Demographics 
Forty-one participants were initially recruited for the study, completed consent 
forms and participated in the required familiarization session.  However, of the original 
41 participants, 36 completed the 28-day research study.  Three participants dropped out 
due to time constraints, one due to an unrelated illness, and one due to apprehension of 
the muscle biopsy procedure.  None of the participants dropped out of the study due to 
side effects related to the study protocol or supplementation.  The baseline demographics 
for the participants are listed in Table 5.   Of the participants that completed the study, 
they were on average 20.2±2 years old, 181±7 cm tall, weighed 82.1±12 kg, and had a 
body fat percentage of 14.7±5 %, with 3.8±3 years of resistance training experience.  No 
significant differences in baseline demographics were observed among groups. 
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Table 5.  Participant Demographics 
 
Group N Age  
(years) 
Height  
(cm) 
Body 
Weight  
(kg) 
Body Fat  
(%) 
Training  
(years) 
KA-L 12 19.8±1.8 180.1±8.4 83.4±13.6 17.0±4.9 3.0±2.5 
KA-H 12 19.5±1.2 181.0±6.3 81.2±8.1 12.8±4.1 4.0±2.9 
CrM 12 21.3±2.8 181.3±6.4 81.8±13.8 14.2±4.7 4.3±3.4 
p-level  0.07 0.91 0.90 0.08 0.55 
Values are means ± standard deviations.  
Data were analyzed by one-way ANOVA. 
 
Compliance, Side Effects, Training, and Diet 
To the best of our knowledge, all participants followed the supplementation 
protocol properly and exhibited 100% compliance based off of the completed 
supplement checklists and empty supplement containers that were returned at each 
testing session.  Furthermore, none of the participants reported any side-effects 
throughout the supplementation period following the assessment of the side-effect 
questionnaires. The workout logs allowed us to examine total training volumes for upper 
and lower body lifts throughout the supplementation period.  A one-way ANOVA 
analysis was run to examine differences among the three groups and Table 6 shows the 
total training volumes for upper and lower body lifts for each group throughout the 28-
day supplementation period.  Results indicated there were no significant differences 
among groups in total upper body training volume (p=0.89) or lower body training 
volume (p=0.55).   
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Table 6.  Training Volume  
 
Group Upper Body  
(kg) 
Lower Body  
(kg) 
KA-L 65,006±35,543 40,631±20,641 
KA-H 74,445±42,340 32,930±20,258 
CrM 69,227±62,251 32,665±19,471 
p-level 0.89 0.55 
Training logs were obtained on all participants (n=36 or 12 per group). 
Values are means ± standard deviations.  
Data were analyzed by one-way ANOVA. 
 
 
  A MANOVA analysis was run to determine differences among groups in 
dietary intake throughout the study.   Table7 presents mean energy intake and 
macronutrient content for each group.  MANOVA univariate analysis revealed a 
significant time effect for daily calorie intake (p = 0.08), suggesting that energy intake 
decreased throughout the study however no significant group x time interactions were 
observed (p=0.81).   A significant time effect was also observed for daily protein intake 
(p = 0.05) again suggesting that protein intake tended to decrease during the study but no 
significant interactions were observed among groups (p = 0.97).   No significant time 
effects were observed for daily carbohydrate (p = 0.40) and fat (p = 0.19) intake and 
with no group x time interactions observed for carbohydrate (p = 0.38) and fat (p = 0.47) 
intake as well. 
Similar results were observed when assessing energy and macronutrient intake 
when expressed relative to body mass.  There was a trend for total energy intake relative 
to body mass (p = 0.06) that suggested a decrease in energy intake over time however no 
group x time interaction was observed (p = 0.06).  There was a significant time effect 
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observed for total protein intake relative to body weight (p = 0.04) suggesting a decrease 
in protein intake over time however no group x time interaction was observed (p = 0.99).   
 
Table 7.  Dietary Caloric and Macronutrient Intake 
Variable Group                               Day 
        0                       7                     28 
  
p-level 
Calories (kcal/day) KA-L 2,167±900 2,202±653 1,998±444 Group 0.29 
KA-H 2,506±645 2,604±670 2,321±677 Time 0.08 
CrM 2,511±582 2,372±735 2,312±394 G x T 0.81 
Protein  
(g/d) 
KA-L 126.3±76 126.2±58 112.4±46 Group 0.65 
KA-H 139.4±46 143.2±54 132.5±60 Time 0.05 
CrM 127.8±28 131.2±40 114.1±35 G x T 0.97 
Carbohydrate (g/d) 
  
KA-L 219.1±73 203.9±79 181.7±53 Group 0.53 
KA-H 221.9±74 216.0±91 206.1±86 Time 0.40 
CrM 231.0±72 226.1±93 242.6±66 G x T 0.38 
Fat  
(g/d) 
KA-L 78.6±38 84.7±27 71.6±16 Group 0.20 
KA-H 99.2±40 105.7±47 94.5±35 Time 0.19 
CrM 91.3±32 81.3±30 83.0±20 G x T 0.47 
Calories KA-L 26.2±10.0  26.6±7.9 24.4±7.2 Group 0.29 
(kcal/kg/d) KA-H 31.4±9.5 32.1±10.5 28.3±9.4 Time 0.06 
 CrM 31.2±7.5 29.0±8.8 28.4±5.8 G x T 0.73 
Protein KA-L 1.50±0.8 1.52±0.7 1.36±0.6 Group 0.58 
(g/kg/d) KA-H 1.75±0.7 1.76±0.8 1.61±0.8 Time 0.04 
 CrM 1.59±0.4 1.61±46 1.41±0.4 G x T 0.99 
Carbohydrate KA-L 2.69±1.0 2.48±0.9 2.21±0.7 Group 0.50 
(g/kg/d) KA-H 2.75±0.9 2.65±1.2 2.46±1.0 Time 0.24 
 CrM 2.87±0.9 2.76±1.1 2.99±0.9 G x T 0.34 
Fat KA-L 0.96±0.4 1.02±0.3 0.87±0.2 Group 0.23 
(g/kg/d) KA-H 1.24±0.6 1.31±0.7 1.16±0.5 Time 0.14 
 CrM 1.14±0.4 1.0±0.4 1.01±0.3 G x T 0.44 
Nutritional records were analyzed on all participants (n=36 or 12 per 
group).  Values are means ± standard deviations.  Absolute and 
relative nutritional data were analyzed by MANOVA.  Greenhouse-
Geisser time and group x time (G x T) interaction p-levels are 
reported with univariate group p-levels.  
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No time or group x time effect was observed for carbohydrate intake relative to body 
weight (p = 0.24) and (p=0.34), respectively.  Similar results were observed for fat 
intake, with no time or group x time effects observed (p = 0.44), respectively. 
Muscle Creatine Analysis 
Table 8 presents muscle free creatine content data.  Muscle samples were 
obtained from 36 participants however there was only sufficient sample to analyze 
samples for 25 out of the 36 participants.  Subjects with missing baseline or day-28 data 
were not included in the analysis.  For two subjects we were missing their Day 7 muscle 
biopsy so their last observed value was used as a replacement.  A MANOVA was run on 
all muscle creatine data and the results are presented in table 8.  The values listed in 
table 8 are expressed in mmol/kg DW and are presented as means ± standard deviations, 
mean changes from baseline and percent changes from baseline.  All values for creatine 
content are expressed in mmol/kg DW.  MANOVA univariate analysis revealed a 
significant time effect in muscle free creatine content expressed in absolute terms 
(p=0.03), suggesting an overall increase in muscle free creatine content for all groups 
over time 58.2±16.0, 59.6±18.6, and 70.1±16.2 mmol/kg DW for days 0, 7 and 28, 
respectively.  A significant time effect was observed for delta changes from baseline for 
all groups (1.4± 20.7, 11.9± 24.0 mmol/kg DW; p=0.03), however no significant group x 
time interactions were observed (KA-L -8.0±22.3, 4.7±27.0; KA-H 1.0±12.8, 9.1±23.2; 
CrM 11.3±23.9, 22.3±21.0 mmol/kg DW).  There was a significant time effect observed 
for percent changes from baseline (7.7±39.4, 30.4±46.2 %; p=0.003) however no 
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significant group x time interactions were observed (KA-L -6.4±37.8, 13.7±42.2; KA-H 
6.2±29.2, 27.3±49.1; CrM 23.5±49.0, 50.4±44.8 %; p = 0.51). 
 
Table 8.  Muscle Creatine Levels 
 
Variable N Group  Day 
 0                           7                        28 
  
p-level 
Cr 
(mmol/kg DW) 
8 KA-L 65.8±15.4 57.9±16.1 70.5±20.9 Group 0.74 
9 KA-H 57.3±17.7 58.3±15.6 66.3±12.6 Time 0.03 
8 CrM 51.5±12.7 62.8±25.0 73.8±15.6 G x T 0.46 
Cr 8 KA-L 0.0±0.0 -8.0±22.3 4.71±27.0 Group 0.14 
(Δ mmol/kg DW) 9 KA-H 0.0±0.0 1.03±12.8 9.07±23.2 Time 0.03 
 8 CrM 0.0±0.0 11.3±23.9 22.3±21.0 G x T 0.46 
Cr  
(Δ %) 
8 KA-L 0.0±0.0 -6.4±37.8 13.7±42.2 Group 0.20 
9 KA-H 0.0±0.0 6.2±29.2 27.3±49.1 Time 0.003 
8 CrM 0.0±0.0 23.5±49.0 50.4±44.8 G x T 0.51 
Values are means ± standard deviations.  Δ represents change from baseline values. 
Sufficient muscle samples were obtained to measure baseline and subsequent Cr on 
25 participants. Missing day-7 data in participants with baseline and day-28 values 
were replaced using the last observed value method (n=2).  Data were analyzed by 
MANOVA with repeated measures.  Greenhouse-Geisser time and group x time (G 
x T) interaction p-levels are reported with univariate group p-levels.  
 
Although there were no overall group differences observed (p=0.14), pairwise 
comparison between the KA-L and CrM groups revealed that changes in muscle creatine 
tended to be greater in the CrM group (KA-L -1.1±4.3, CrM 11.2±4.3 mmol/kg DW, 
p=0.053 [mean±SEM]; KA-L 2.4±8.5, CrM 24.6±8.5 %, p=0.078 [mean±SEM]).  Figure 
2 represents percent changes in muscle creatine over time for each group.  The results 
from the creatine analysis provides supporting evidence to reject hypothesis 1 which 
stated that there will be a significant difference between groups in phosphagen levels as 
measured by muscle biopsies after 7 and 28-days of supplementation. 
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Figure 2. Percent Changes in Muscle Creatine 
 
Body Composition 
A MANOVA was run to assess changes in body composition variables which 
included body weight (kg), fat free mass (kg), fat mass (kg) and percent body fat.  Table 
9 displays the results from all body composition analysis.  Bodyweight increased in all 
groups over time (1.0±1.9, 1.42±2.5 kg, p<0.001) with no significant group x time 
interaction effects observed among groups (KA-L 0.7±0.83, 0.9±1.6; KA-H 1.7±2.9, 
2.3±3.7; CrM 0.6±1.1, 1.1±1.4 kg, p=0.35) after 7 and 28-days of supplementation, 
respectively.  No significant differences were observed among groups over time for fat 
mass (-0.1±0.7, -0.1±1.3 kg, p = 0.82) and no group x time interactions were observed 
(KA-L 0.1±0.5, 0.2±1.1; KA-H -0.1±0.5, -0.1±1.3; CrM -0.3±0.7, -0.4±1.5 kg, p = 0.73). 
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Table 9.  Body Composition    
 
Marker Group                                Day 
0                    7                     28 
 
 
 
p-level 
Body Weight  
(kg) 
KA-L 83.4±13.6 84.1±14.0 84.3±13.6 Group 0.94 
KA-H 81.2±8.1 83.0±9.7 83.5±10.3 Time 0.001 
CrM 81.8±13.8 82.3±13.6 82.9±13.0 G x T 0.35 
Fat Mass 
(kg) 
 
KA-L 13.5±5.4 13.7±5.9 13.8±5.8 Group 0.11 
KA-H 9.7±3.2 9.6±3.1 9.6±3.1 Time 0.82 
CrM 11.0±5.3 10.7±5.4 10.6±4.4 G x T 0.73 
Fat-Free Mass KA-L 61.3±8.7 61.7±8.6 61.7±8.8 Group 0.77 
(kg) KA-H 63.5±8.0 64.4±8.0 64.7±8.4 Time 0.001 
 CrM 62.3±9.8 63.0±9.6 63.4±9.9 G x T 0.43 
Body Fat Percent 
(%) 
 
KA-L 17.0±4.9 17.0±5.5 17.2±5.4 Group 0.06 
KA-H 12.8±4.1 12.5±3.8 12.5±3.6 Time 0.41 
CrM 14.2±4.7 13.7±5.0 13.7±4.2 G x T 0.77 
Total Body Water 
(%) 
KA-L 37.8±5.0 37.2±4.4 35.9±3.3 Group 0.26 
KA-H 37.4±2.9 35.1±2.6 34.1±1.7 Time 0.00 
CrM 36.7±2.7 35.8±3.0 33.9±1.5 G x T 0.71 
Values are means ± standard deviations.  DEXA body composition 
and BIA determined body water were determined on 36 participants 
(12 per group).  Body composition variables were analyzed by 
MANOVA with repeated measures.  Greenhouse-Geisser time and 
group x time (G x T) interaction p-levels are reported with univariate 
group p-levels.  
 
Fat-free mass significantly increased over time for all groups (0.67±1.0, 0.89±1.2 
kg, p<0.001) with no significant group x time interaction effects observed among groups 
(KA-L 0.42±1.2, 0.37±1.3; KA-H 0.96±0.9, 1.2±1.4; CrM 0.6±0.8, 1.1±0.9 kg, p=0.43).   
Figure 3 represents changes in fat free mass over time for each group. 
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Figure 3. Changes in Fat Free Mass 
 
No significant differences were observed over time in body fat percent for all 
groups (-0.28±1.0, -0.22±1.4 %, p=0.41) and no significant group x time interactions 
were observed among groups (KA-L -0.04±1.3, 0.15±1.2; KA-H -0.28±0.7, -0.31±1.6; 
CrM -0.53±0.9, -0.50±1.4 %, p=0.77) after 7 and 28-days of supplementation, 
respectively.  Total body water expressed as a percentage of bodyweight significantly 
decreased over time for all groups (-1.25±3.7, -2.68±3.4 %, p<0.001) with no significant 
group x time interactions observed among groups (KA-L -0.58±4.1, -1.95±4.4; KA-H -
2.25±2.0, -3.28±3.1; CrM -0.92±4.6, -2.82±2.6 %, p=0.71).  Results from the body 
composition analysis provide evidence for a failure to reject the null hypothesis for 
Hypothesis 3, which stated there will be no significant differences between groups in 
body composition as measured by DEXA after 7 and 28-days of supplementation.  
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 Training Adaptations 
There was a significant increase in 1RM for bench press in all groups over time 
(97.6±22.3 to 101.3±22.6 kg, p<0.001) with no significant group x time interactions 
observed among groups in changes in bench press 1RM from baseline (KA-L 3.22±1.5, 
KA-H 3.3±6.8, CrM 4.5±3.7 kg, p=0.73).  Figure 4 shows the changes in 1RM bench 
press over time.    
 
Figure 4. Changes in Bench Press 1RM 
 
Table 10 shows upper and lower body 1RM strength data observed for each 
group.   There was no significant difference observed in hip sled/leg press 1RM over 
time (449.5±162, 471.1±167, p=0.33) or a significant interaction observed among groups 
in changes in hip sled/leg press 1RM (KA-L 8.7±111, KA-H 68.8±96, CrM -13.3±185 
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kg, p=0.33).  The results of the maximal strength analysis provide evidence which fails 
to reject the null hypothesis of hypothesis 5 which stated that there will be no significant 
difference between groups in strength as measure by 1RM on the leg press and bench 
press exercises after 28-days of supplementation. 
 
Table 10.  One Repetition Maximum Strength 
 
Variable  
N 
Group Day 
        0                                   
28 
  
p-level 
Upper 
Body 
(kg) 
12 KA-L 95.3±25.4 98.6±24.7 Group 0.89 
11 KA-H 98.4±18.2 101.7±17.3 Time 0.001 
12 CrM 99.12±24.0 103.7±26.1 G x T 0.73 
Lower 
Body  
(kg) 
12 KA-L 445.3±182 454.1±155 Group 0.52 
12 KA-H 465.4±117 539.0±163 Time 0.35 
12 CrM 439.1±189 425.8±175 G x T 0.31 
Values are means ± standard deviations.  Data were analyzed by 
MANOVA with repeated measures.  Greenhouse-Geisser time and 
group x time (G x T) interaction p-levels are reported with 
univariate group p-levels.  
 
Table 11 shows results for the anaerobic capacity observed for each group.   A 
MANOVA analysis was run in order to assess changes in anaerobic capacity variables.   
Table 11 represents these variables expressed as means ± standard deviations.  There 
was a significant time effect observed in all groups for average power (0.005), peak 
power (p=0.003), and total work (p=0.005), with no significant group x time interactions 
observed among groups.  Mean power during the anaerobic capacity sprint test increased 
in all groups over time (-0.8±34.9, 19.1±44.5 W, p=0.005) after 7 and 28-days of 
supplementation with no significant group x time effects observed among groups (KA-L 
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-6.9±25.2, 2.1±40.6; KA-H 13.7±34.7, 28.0±45.8; CrM -8.1±41.6, 27.9±45.8 W, 
p=0.21).  Peak power during the anaerobic capacity sprint test increased in all groups 
over time (157.5±326.0, 228.7±394.3 W, p=0.003) after 7 and 28-days of 
supplementation, however no significant group x time interaction was observed among 
groups (KA-L 119.2±291.8, 311.2±418.8; KA-H 209.2±262.8 287.1±382.6; CrM 
148.6±419.9 92.8±375.7 W, p=0.48). 
 
Table 11.  Wingate Anaerobic Sprint Capacity 
 
Variable  
N 
Group Day 
0                           7                        28 
  
p-level 
Mean 
Power 
(W) 
12 KA-L 658±136 651±134 660±138 Group 0.61 
11 KA-H 689±99 703±113 717±114 Time 0.005 
12 CrM 660±119 652±108 688±105 G x T 0.21 
Peak 
Power 
(W) 
12 KA-L 1,274±259 1,393±286 1,585±526 Group 0.50 
11 KA-H 1,329±285 1,538±389 1,616±378 Time 0.003 
12 CrM 1,478±376 1,626±281 1,571±409 G x T 0.48 
Total 
Work  
(J) 
 
12 KA-L 19,728±4,076 19,450±3,910 19,792±4,153 Group 0.59 
11 KA-H 20,681±2,968 21,093±3,387 21,523±3,432 Time 0.005 
12 CrM 19,799±3,564 19,497±3,210 20,573±3,128 G x T 0.22 
Values are means ± standard deviations.  Data were analyzed by MANOVA with 
repeated measures.  Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels.  
 
Total work performed on the anaerobic capacity sprint test increased in all 
groups over time (-69±1,030, 552±1,361 J, p=0.02) after 7 and 28-days of 
supplementation with no significant group x time effects observed among groups (KA-
L -278±676, 64±1,216; KA-H 412±1,041, 842±1,369; CrM -301±1,224, 775±1,463 J, 
p=0.32).   Figure 5 presents the percent changes in total work done during the anaerobic 
sprint capacity tests over time.  These results provide evidence to reject hypothesis 4 
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which stated that there will be a significant difference between groups in anaerobic 
capacity as measured by the 30 second Wingate test on a Lode cycle ergometer after 7 
and 28 days of supplementation. 
 
 
Figure 5. Percent Change in Total Work 
 
Clinical Chemistry Panels 
A MANOVA analysis was run in order to assess changes in blood lipid data.  
Table 12 presents blood lipid data observed throughout the study  There was a 
significant time effect observed for high-density lipoprotein (HDL, p=0.03) , however no 
group x time interactions were observed among groups (p=0.64).  There was also a 
significant time effect observed for the ratio of TCHL to HDL (p=0.04), however no 
significant group x time interactions were observed (p=0.09).  No significant time effects 
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were observed for total cholesterol (TCHL, p=0.15), low-density lipoprotein (LDL, 
p=0.42), and triglycerides (TRIG, p=0.07).  Furthermore, no group x time interactions in 
total cholesterol (TCHL, p=0.10) or triglycerides (TRIG, p=0.45) were observed.   
 
Table 12.  Serum Lipids and Glucose    
 
Marker  
N 
Group                                    Day 
0                    7                     28 
 
 
 
p-
level 
TCHL 
(mg/dl) 
11 KA-L 149.1±25 153.0±23 149.9±28 Group 0.91 
12 KA-H 153.3±26 152.3±28 157.5±22 Time 0.15 
12 CrM 156.3±20 147.3±19 158.9±21 G x T 0.10 
HDL  
(mg/dl) 
11 KA-L 48.8±11.3 51.0±9.3 52.9±11.4 Group 0.42 
12 KA-H 53.0±16.0 53.9±18.4 53.6±14.4 Time 0.03 
12 CrM 45.6±6.5 47.6±7.3 48.5±8.4 G x T 0.64 
TCHL: 
HDL 
Ratio 
11 KA-L 3.16±0.7 3.09±0.6 2.92±0.7 Group 0.34 
12 KA-H 3.03±0.6 2.95±0.5 3.04±0.5 Time 0.04 
12 CrM 3.48±0.6 3.15±0.6 3.36±0.7 G x T 0.09 
LDL 11 KA-L 83.4±16* 86.5±16 81.4±18* Group 0.66 
(mg/dl) 12 KA-H 79.4±18* 82.7±19 83.7±16* Time 0.42 
 12 CrM 89.8±20 81.4±15† 92.5±17 G x T 0.005 
TRIG 
(mg/dl) 
11 KA-L 84.5±33 77.3±30 78.5±37 Group 0.20 
12 KA-H 105.1±37 78.4±26 101.1±27 Time 0.07 
12 CrM 104.1±28 92.1±30 89.6±30 G x T 0.45 
Glucose 
(mg/dl) 
11 KA-L 93.0±5.1 90.5±8.2 93.6±4.7 Group 0.44 
12 KA-H 91.1±6.6 92.7±8.1 90.4±6.9 Time 0.57 
12 CrM 90.5±9.6 89.6±5.5 88.3±6.3 G x T 0.67 
Values are means ± standard deviations.  Lipid data were analyzed by 
MANOVA with repeated measures.  Greenhouse-Geisser time and group x 
time (G x T) interaction p-levels are reported with univariate group p-levels.  
Glucose data were analyzed by repeated measures univariate ANOVA.  † 
represents p<0.05 difference from baseline.  * represents p<0.05 difference 
from CrM. 
 
 
Some group x time effects were observed among groups in low-density 
lipoprotein (LDL) levels (p=0.005) with LDL levels significantly decreasing after the 
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loading phase in the CrM group.  However, values remained low, near baseline and still 
within the normal range.  No significant differences were observed among groups in 
blood glucose (p=0.67) over time. 
A MANOVA analysis was run in order to assess changes in markers of 
catabolism.  Table 13 shows markers of catabolism and bone status for each group over 
time.  Significant time effects were observed for aspartate aminotransferase (AST, 
p=0.02), however no significant group x time interactions were observed (p=0.68).  A 
significant time effect was observed for alanine aminotransferase (ALT, p=0.05), 
however no group x time interactions were observed (p=0.48).  Univariate MANOVA 
found no significant group x time interactions in blood urea nitrogen (BUN, p=0.75), 
BUN to creatinine ratio (p=0.24), total protein (p=0.84), and total bilirubin (TBIL, 
p=0.26).  Serum creatinine levels increased in all groups (p<0.001) over time with a 
significant group x time interaction demonstrating higher doses of creatine in the CrM 
and KA-H groups promoting significantly greater increases in serum creatinine (p=0.03) 
than the KA-L group.  However, creatinine levels in the CrM and KA-H groups were 
only 0.1 – 0.2 mg/dL greater than the KA-L group, which were again well within normal 
values for active individuals, and of no clinical significance.  MANOVA analysis of 
bone related markers found no significant time effects for bone mineral content 
(p=0.49), albumin (ALB, p=0.73), globulin (GLOB, p=0.85), the ratio of ALB to GLOB 
(p=0.70), calcium (p=0.51), or alkaline phosphatase (ALK, p=0.29).   Likewise, no 
significant interactions among groups were observed in bone mineral content (p=0.66),  
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Table 13.  Markers of Catabolism and Bone Status.   
 
Marker  
N 
Group Day 
0                    7                     28 
 
 
 
p-level 
BUN  
(mg/dl) 
11 KA-L 16.0±5.3 15.3±4.9 15.6±5.1 Group 0.89 
12 KA-H 16.1±3.3 16.6±3.9 16.6±3.6 Time 0.70 
12 CrM 16.4±3.2 15.7±2.7 16.1±4.7 G x T 0.75 
Creatinine 11 KA-L 1.04±0.08 1.08±0.11 1.13±0.10† Group 0.07 
(mg/dl) 12 KA-H 1.07±0.14 1.23±0.18†* 1.26±0.13†* Time 0.001 
 12 CrM 1.11±0.19 1.28±0.20†* 1.23±0.15†* G x T 0.03 
BUN:CRN Ratio 11 KA-L 15.5±5.1 14.5±5.6 14.1±5.6 Group 0.83 
12 KA-H 15.1±3.4 13.7±3.4 13.3±3.4 Time 0.001 
12 CrM 15.2±3.7 12.4±2.6 13.2±3.8 G x T 0.24 
AST  
(U/L) 
11 KA-L 25.4±9.6 26.5±8.4 29.5±12.9 Group 0.62 
12 KA-H 27.3±10.5 25.6±8.3 32.0±12.0 Time 0.02 
12 CrM 24.9±7.9 23.8±7.5 26.3±7.8 G x T 0.70 
ALT  
(U/L)  
11 KA-L 21.5±11.2 23.5±14.2 28.7±19.4 Group 0.50 
12 KA-H 24.1±15.6 22.3±12.2 27.3±9.1 Time 0.05 
12 CrM 21.3±7.34 18.0±4.2 21.3±5.5 G x T 0.48 
Total Protein  
(g/dl) 
 
11 KA-L 7.4±0.6 7.4±0.4 7.4±0.4 Group 0.87 
12 KA-H 7.3±0.3 7.3±0.3 7.3±0.2 Time 0.88 
12 CrM 7.3±0.2 7.3±0.2 7.4±0.3 G x T 0.84 
TBIL 
(mg/dl) 
11 KA-L 0.84±0.7 0.75±0.3 0.76±0.3 Group 0.60 
12 KA-H 0.88±0.5 0.89±0.5 0.77±0.4 Time 0.90 
12 CrM 0.63±0.2 0.71±0.2 0.77±0.2 G x T 0.26 
Bone Mineral 11 KA-L 2,517±404 2,503±409 2,505±398 Group 0.59 
Content (g) 12 KA-H 2,632±457 2,604±466 2,615±456 Time 0.49 
 12 CrM 2,446±344 2,456±0.2 2,441±351 G x T 0.66 
Albumin 
(g/dl) 
11 KA-L 4.80± 0.3 4.81±0.4 4.81±0.2 Group 0.95 
12 KA-H 4.83±0.2 4.74±0.2 4.78±0.1 Time 0.73 
12 CrM 4.82±0.2 4.80±364 4.79±0.2 G x T 0.89 
Globulin 
(g/dl) 
11 KA-L 2.60±0.4 2.63±0.3 2.55±0.3 Group 0.90 
12 KA-H 2.56±0.3 2.58±0.2 2.52±0.3 Time 0.85 
12 CrM 2.55±0.3 2.54±0.2 2.62±0.3 G x T 0.42 
Alb:Glob Ratio 11 KA-L 1.88±0.3 1.85±0.2 1.90±0.2 Group 0.98 
12 KA-H 1.90±0.1 1.86±0.2 1.91±0.1 Time 0.70 
12 CrM 1.88±0.2 1.90±0.2 1.84±0.2 G x T 0.45 
Calcium  
(mg/dl) 
11 KA-L 9.87±0.5 9.85±0.5 9.76±0.4 Group 0.42 
12 KA-H 9.83±0.2 9.81±0.4 9.84±0.2 Time 0.51 
12 CrM 9.77±0.3 9.63±0.4 9.67±0.3 G x T 0.76 
ALK 
(U/L) 
11 KA-L 82.0±16.4 84.1±20.5 83.9±17.0 Group 0.88 
12 KA-H 81.1±29.7 83.8±30.3 87.1±27.6 Time 0.29 
12 CrM 78.9±20.7 80.6±26.4 78.8±23.1 G x T 0.65 
Values are means ± standard deviations.  Data were analyzed by MANOVA with 
repeated measures.  Greenhouse-Geisser time and group x time (G x T) interaction 
p-levels are reported with univariate group p-levels.  † represents p<0.05 
difference from baseline. * represents p<0.05 difference from KA-L. 
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 albumin (ALB, p=0.89), globulin (GLOB, p=0.42), the ratio of ALB to GLOB (p=0.45), 
calcium (p=0.76), or alkaline phosphatase (ALK, p=0.65).  
 Table 14 presents serum electrolyte data.  Univariate MANOVA analysis revealed 
some small time effects in chloride levels (p=0.008) and a trend toward an interaction in 
potassium levels (p=0.08) but the small changes observed would have no clinical 
significance.   No significant interactions were observed in sodium levels (p=0.57).   
 
Table 14.  Serum Electrolyte Status.    
 
Marker  
N 
Group                                    Day 
0                    7                     28 
 
 
 
p-
level 
Sodium 
(mmol/L) 
11 KA-L 140.1±2.3 139.9±1.1 140.0±1.3 Group 0.98 
12 KA-H 139.9±2.3 139.7±2.4 140.3±2.1 Time 0.28 
12 CrM 140.8±2.1 139.3±1.4 139.7±1.6 G x T 0.57 
Potassium  
(mmol/L) 
11 KA-L 4.54±0.3 4.86±0.4 4.82±0.3 Group 0.65 
12 KA-H 4.89±0.5 4.71±0.6 5.00±0.3 Time 0.11 
12 CrM 4.74±0.4 4.93±0.4 4.81±0.4 G x T 0.08 
Chloride 
(mmol/L) 
 
11 KA-L 103.3±2.2 103.0±2.4 103.8±1.9 Group 0.21 
12 KA-H 102.4±2.2 101.5±2.2 102.6±2.4 Time 0.008 
12 CrM 104.3±2.2 102.3±1.7 103.1±1.8 G x T 0.21 
Values are means ± standard deviations.  Data were analyzed by MANOVA 
with repeated measures.  Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels.  
 
Finally, Table 15 shows whole blood markers assessed throughout the study.  
Univariate MANOVA analysis revealed no significant interactions observed among 
groups in white blood cell count (WBC, p=0.45), red blood cell count (RBC, p=0.64), 
hematocrit (p=0.65), hemoglobin (p=0.59), mean corpuscular volume (MCV, p=0.56), 
mean corpuscular hemoglobin (MCH, p=0.44), mean corpuscular hemoglobin 
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concentration (MCHC, p=0.68), red blood cell distribution width (RBCDW, p=0.92), or 
platelet count (p=0.48).   These results provide evidence to for the failure to reject the 
null of hypothesis 2 which stated that there will be no significant difference between 
groups in markers of clinical health and safety after 7 and 28 days of supplementation. 
 
Table 15.  Whole Blood Markers.   
 
Marker  
N 
Group Day 
0                    7                     28 
 
 
 
p-level 
WBC  
(x103/ul) 
9 KA-L 5.73±0.6 6.13±0.5 6.17±1.5 Group 0.95 
12 KA-H 5.83±1.1 5.76±0.9 6.36±1.1 Time 0.16 
12 CrM 5.97±1.2 5.73±1.0 5.98±1.2 G x T 0.45 
RBC 
(x106/ul) 
9 KA-L 5.44±0.4 5.38±0.5 5.44±0.3 Group 0.28 
12 KA-H 5.10±0.4 5.18±0.3 5.23±0.3 Time 0.91 
12 CrM 5.42±0.5 5.41±0.5 5.35±0.7 G x T 0.64 
Hematocrit 9 KA-L 48.4±3.4 47.9±4.3 48.1±2.9 Group 0.17 
(%) 12 KA-H 46.5±3.2 47.0±2.8 47.4±1.8 Time 0.96 
 12 CrM 45.9±2.3 46.1±2.5 45.2±5.4 G x T 0.65 
Hemoglobin 
(g/dl) 
9 KA-L 16.0±1.6 16.0±1.6 16.0±1.2 Group 0.21 
12 KA-H 15.2±1.2 15.7±1.0 15.6±0.7 Time 0.60 
12 CrM 15.1±0.9 15.2±1.1 14.9±2.0 G x T 0.62 
MCV 
(fL) 
 
9 KA-L 89.0±2.8 88.9±2.9 88.3±2.8 Group 0.10 
12 KA-H 91.1±3.5 90.8±3.1 90.7±3.6 Time 0.03 
12 CrM 85.4±9.2 85.7±9.5 85.0±9.1 G x T 0.56 
MCH 
(pg/cell) 
9 KA-L 29.4±1.5 29.6±1.2 29.3±1.2 Group 0.34 
12 KA-H 29.8±1.6 30.2±1.5 28.4±4.9 Time 0.20 
12 CrM 28.1±3.5 28.3±3.7 27.9±3.3 G x T 0.44 
MCHC 
(g/dl) 
9 KA-L 33.0±1.3 33.3±0.9 33.2±0.9 Group 0.73 
12 KA-H 32.8±0.9 33.3±0.8 32.9±0.6 Time 0.22 
12 CrM 32.9±1.1 32.9±1.3 32.9±0.8 G x T 0.68 
RBCDW 
(%) 
9 KA-L 13.0±0.5 13.0±0.9 12.9±0.7 Group 0.34 
12 KA-H 13.8±1.1 13.7±1.0 13.5±1.5 Time 0.41 
12 CrM 13.7±1.4 13.7±1.7 13.6±1.6 G x T 0.92 
Platelet Count 
(x103/ul) 
 
9 KA-L 266±45 266±52 280±45 Group 0.12 
12 KA-H 253±54 248±62 269±65 Time 0.32 
12 CrM 222±69 222±74 216±65 G x T 0.48 
Values are means ± standard deviations.  White and red cell whole 
blood markers were analyzed by MANOVA with repeated 
measures.  Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels.  
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
The purpose of this study was to examine if ingesting 1.5 g/day of Kre-Alkalyn® 
(KA) for 28-days, or 28-days of creatine equivalent doses of KA was more efficacious 
than supplementation with CrM (20 g/d for 7-days and 5 g/d for 21-days) on muscle 
creatine retention, body composition, strength, anaerobic capacity and markers of 
clinical health.  Furthermore, this study sought out to determine if KA had fewer side-
effects than CrM.  The results of the present study clearly show that a buffered form of 
creatine is no more efficacious than creatine monohydrate in terms of improving creatine 
retention, training adaptations and markers of clinical health. 
Muscle Creatine 
Claims by the manufacturers of Kre-Alkalyn, state that their product promotes 
greater bioavailability of creatine and therefore a greater amount of creatine can be 
absorbed by the muscles.  The manufacturer’s claim that KA has less conversion of 
creatine to creatinine during the digestive process compared to CrM because it is 
“bufferd” or “pH-correct.”[39]  They claim this despite the fact that previous research 
has shown that nearly 99% or orally ingested creatine is either taken up by the tissues or 
excreted in the urine[35, 36].  The manufacturer’s claim that KA is “up to ten times more 
powerful than ordinary Creatine.” It is because of this claim that the recommended dose 
of 1.5 g/d of KA (KA-L) as well as a creatine monohydrate equivalent dose (20 g/d for 
7-days and 5 g/d for 21 days) of KA (KA-H) was used in order to compare KA to CrM.  
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The present study failed to show any significant differences in creatine retention 
between groups suggesting that KA is no more efficacious than CrM when it comes to 
improving the bioavailability of creatine.  In the present study, muscle creatine content 
increased 34.6±50 % after 7-d of 20g of CrM, compared to -5.9±35 and 6.2±29 % 
following 7-d of supplementation with 1.5 g/d (KA-L) and 20 g/d (KA-H) of KA.  
Similar results have been found with previous research showing that acute ingestion of 
20g of CrM can increase muscle creatine content 10-40% after 5-7 d of supplementation 
[13, 14, 17, 20].  When KA-L was compared to CrM there was a trend of CrM 
increasing creatine content to a greater extent compared to KA-L (KA-L -5.9±35; CrM 
34.6±50 %, p=0.069) but results were not statistically significant.   Similar results were 
seen after a maintenance dose of 5g for 21-d as the CrM group experienced an increase 
of 50.4±45% in creatine compared to 11.9±40 and 27.3±49 % in the KA-L and KA-H 
groups, respectively.  When KA-L was compared to CrM alone, these changes were 
statistically significant (p=0.038).  These results are directly in opposition to claims 
made by the manufacturers stating that a recommended dose of KA supplementation (1.5 
g/d) promotes a greater creatine uptake compared to CrM supplementation.   In fact, 
pairwise comparison of the mean group change from baseline in the CrM groups was 11 
times greater than the change observed following recommended doses of KA (KA-L -
1.1±4.3, CrM 11.2±4.3 mmol/kg DW [mean±SEM],p=0.053) after 7-days of 
supplementation, however the overall group effect was not statistically significant 
(p=0.14).  Similar results were seen after 28-days of supplementation, again showing 
substantially greater increases in creatine content in the CrM group 22.3±21.0 mmol/kg 
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DW compared to 4.71±27.0 mmol/kg DW in the KA-L group.  This is further evidence 
that KA is no more efficacious than CrM and the claims made by the manufacturers are 
not supported by the results of the present study. 
Body Composition 
Results of the present study indicated that there was a significant increase in 
bodyweight seen in all groups as is common after acute and long-term creatine 
supplementation.  Typical weight gain from creatine supplementation ranges between 1-
2 kg in total body weight [7, 14, 64].  Kreider et al. [19] suggested that short-term 
supplementation (5-7 days) with 20g/d can often lead to increases in body mass of up to 
1.6 kg which is similar to the gains in body mass (KA-L 0.7±0.83, KA-H 1.7±2.9, CrM 
0.56±1.1 kg) seen in the present study after 7-d of supplementation.   There were no 
significant differences in bodyweight observed among groups.  All groups also 
experienced a significant increase in fat-free mass with an average gain 0.67±0.9 and 
0.89±1.2 kg, after 7 and 28-d, respectively.  These gains in FFM are similar to those seen 
in previous creatine supplementation studies [19, 68, 112, 113].   No significant 
differences were observed in total body water, as a percentage of total bodyweight, 
among groups; which suggests the changes in body mass were not attributable to body 
water changes and likely due to increases in fat-free mass.   Furthermore, no significant 
changes in body fat percent were observed, suggesting that the observed changes in 
bodyweight were of an equal ratio of fat-free mass to fat mass.  Because significant 
differences were observed among total volume of training or dietary intake, the 
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differences observed in body weight and fat-free mass are likely attributable to the 
supplementation strategies utilized. 
Training Adaptations 
Several studies have shown improvements in strength and power following 
creatine supplementation [47, 60, 61, 77, 114].  In the present study, there was a 
significant increase in upper-body strength observed in all groups with no differences 
among groups.  The average increase in bench press 1RM for all groups was 
approximately 4%.  Similar improvements in bench press 1RM have been observed 
following creatine supplementation strategies.  Earnest et al. found a 6% increase in 
bench press 1RM following 28 days of creatine supplementation in resistance trained 
males[80].   Similarly, Kelly et al. found an 8% increase in bench press 3RM following 
26-days of creatine supplementation in resistance trained males.  No significant changes 
in lower body strength were observed for any of the groups.   This may be due to the fact 
that, on average, the participants had a greater training volume for upper body (~69,560 
kg) compared to lower body (35,410 kg) throughout the duration of the study.  This was 
an unexpected outcome from analyzing the workouts but may be typical for recreational 
weight lifters and perhaps a limitation of allowing participants to follow their own 
routines.   
The manufacturers of Kre-Alkalyn® also claim that their product has a greater 
capacity to increase “raw” power and training capacity when compared to CrM.   
Previous research has shown improvements in anaerobic cycle ergometer performance in 
the range of 10-25% [88, 115-117].  For example, Ziegenfuss et al. found increases in 
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total work and peak power during consecutive high-intensity sprints on a cycle 
ergometer [118]. The results of the present study are in accordance with these findings.  
There was a significant increase in total work done during the Wingate test in all groups 
(-69±1,030, 552±1,361 J, p=0.02) after 7 and 28-days of supplementation which equated 
to approximately a 3% improvement after 28-days for all groups.  However no 
significant differences were observed among groups.  Similar improvements were seen 
in peak power (+20%) and mean power (+3%) after 28-days of supplementation for all 
groups with no significant differences observed among groups.  Therefore, it can again 
be assumed that KA supplementation is no more effective than CrM supplementation in 
terms of improving anaerobic performance. 
Markers of Clinical Health 
Creatine supplementation has repeatedly been shown to have minimal negative 
side-effects with little to no effect on markers of clinical health and safety [21].  In the 
present study, neither manufacturers recommended doses or equivalent loading doses of 
KA resulted in any negative side-effects or health outcomes. These findings suggest that 
a buffered form of creatine is just as safe to consume as CrM with minimal side-effects.  
There was a trend that higher doses of supplemental creatine promoted greater increases 
in serum creatinine (KA-L: 1.04±0.08, 1.08±0.11, 1.1±0.1; KA-H: 1.1±0.14, 1.2±0.18, 
1.3±0.13; CrM: 1.1±0.19, 1.3±0.2, 1.2±0.15 mg/dl, p=0.071) after 0, 7 and 28-days of 
supplementation, respectively.  However, these values remained well within normal 
values for active individuals (i.e., <1.28±0.20 mg/dl).  Furthermore, there were no 
significant differences in creatinine levels observed among groups throughout the study.  
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This is in direct opposition of the claim made by the manufacturers of Kre-Alkalyn® 
stating that because Kre-Alkalyn is a “buffered” creatine it won’t convert to creatinine as 
does other forms of creatine.  Furthermore, these results also refute the manufacturer’s 
claims which state that KA is a safer form of creatine with less side-effects. 
Cost Analysis 
The results of this study indicate that CrM supplementation results in a greater 
creatine uptake when compared to the recommended dose of KA (1.5 g/d).  When 
comparing the costs of these two products this difference becomes important.   Kre-
Alkalyn typically has 240 capsules per bottle with a recommended serving size of 1.5 
grams per day (2 capsules).   The average retail cost for a bottle is about $20.00 which 
comes about to be $0.16 cents per g or $161.11 per kg.  Creatine monohydrate on the 
other hand typically sells for $20.00-$30.00 per kg ($0.02 to $0.03 cents per gram).  
Therefore, for a much cheaper price you can get an equivalent product with creatine 
monohydrate. 
Future Direction and Recommendations for Additional Research 
 There are constantly new products appearing in today’s nutritional supplement 
market.  It is important that these products be tested by independent researchers before 
exaggerated claims are made my manufacturers and marketing strategies overshadow the 
true effects of the actual product.  Furthermore, it is important that the safety of these 
products is also investigated especially with long-term supplementation before they are 
released into the market.  Studies, such as the current one, should be done in order to 
monitor the safety and efficacy of new products.  Acute and long-term supplementation 
 78 
 
 
studies should be utilized in order to assess acute and chronic effects of the supplement 
on training adaptations and markers of clinical health.  Future studies similar to the 
present one could be replicated but with a longer supplementation period or even a 
standardized exercise protocol throughout the study in order to assess the long-term 
adaptations to Kre-Alkalyn. 
Conclusion 
Supplementation of the diet with recommended doses of Kre-Alkalyn (1.5 
grams/day) and equivalent (20 g/day for 7-days and 5 g/d for 21-days) doses does not 
promote greater increases in muscle creatine content or training adaptations in 
comparison to creatine monohydrate.   Additionally, there was no evidence to support 
claims that Kre-Alkalyn is associated with fewer side effects or is a safer form of 
creatine to consume compared to creatine monohydrate.   These findings refute claims 
that Kre-Alkalyn is a more efficacious and safer form of creatine than creatine 
monohydrate.   However, it should me mentioned that there were some limitations to the 
current study design.  There are also large variations seen when conducting human 
research and conduction human tissue assays.  Similar variations are often seen 
following performance tests in which large standard deviations are common and 
sometimes make it difficult to detect statistical significance.  Another limitation of the 
present study is a lack of a control group.  The addition of a control group and/or more 
subjects may have increased the statistical power.  In summary, results of the present 
study indicate that KA is no more effective than CrM and just as safe to consume. 
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APPENDIX A 
CONSENT FORM 
 
Comparison of Different Forms of Creatine on Creatine Availability, Retention, and Training 
Adaptations 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to whether 
or not to participate in this research study.  If you decide to participate in this study, this form will 
also be used to record your consent. 
 
You have been asked to participate in a research project studying different forms of creatine.  The 
purpose of this study is to determine the effects of ingesting loading doses of creatine 
monohydrate (CM) and Kre-alkalyn (KA) on muscle creatine retention and muscle phosphagen 
levels; and, the effects of 28-days of CM and KA supplementation on body composition, strength, 
and anaerobic capacity.  You were selected to be a possible participant because you met all 
entrance criteria.  This study is being sponsored/funded by AlzChem Trostberg GmbH.   
 
What will I be asked to do? 
If you agree to participate in this study, you will first be asked to sign an Informed Consent 
statement in compliance with the Human Subject’s Protection Program (HSPP) at Texas A&M 
University and the American College of Sports Medicine.  You will then be familiarized to the study 
requirements, food log recording and tests to be conducted during the study.  This session will 
take approximately one hour to complete.  You will then be provided eight 3 L urine collection 
containers in order to collect 24 hr. urine samples on days 0,1,2,3,4,5,6 and 7, and will be asked 
to record the number of times you urinate each day as well as your specific fluid intake.  The 24 
hr. baseline urine sample time parameter will be initiated at 8:00 a.m. the day before 
supplementation protocols begin.  You will be asked to report daily to the Exercise & Sport 
Nutrition Lab (ESNL) between 7:00 and 8:00 a.m. in order to drop off your urine samples.  Prior to 
reporting to the lab for baseline testing, you will record all food that you eat on dietary record forms 
for four days (including one weekend day).  You will not exercise for 48 hours nor eat for 12 hours 
prior to reporting to the lab for baseline testing.  You will then undergo a battery of tests as 
described in Table 1 below.  You will fill out a Demographic Form, a Health History Form, an 
Exercise History Form and a Radiation Safety Form. You will also be required to report any 
adverse side effects that you may experience on a weekly basis.  .   
 
You will then continue with the tests as described in Table 1.  You will first be weighed and have 
your height measured.  You will then be asked to provide a muscle sample from your leg muscle 
for fiber type analysis.  Muscle biopsies will be obtained using the Bergstroem technique (3 total 
biopsies during the study), which involves a ¼” incision on the skin and the use of a 5 mm biopsy 
needle.  Local anesthetic will be used prior to the incision and biopsy.  Percutaneous muscle 
biopsies (50-70 mg) will be obtained from the middle portion of the vastus lateralis muscle (thigh 
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muscle covering the outermost portion of the front of the leg) of one leg at the midpoint between 
the knee and hip joint at a depth between 1 and 2 cm.  For the remaining biopsies, attempts will 
be made to extract tissue from approximately the same depth and area as the initial biopsy by 
using the pre-biopsy scar, depth markings on the needle, and a successive incision that will be 
made approximately 0.5 cm to the former from medial to lateral.  All these procedures will be 
conducted again at 1 and 4 weeks into the study.  You will then donate about 20 milliliters (4 
teaspoons) of venous blood from a vein in your arm.  Blood samples will be obtained by 
standard/sterile procedures using a needle inserted into a vein in your arm.  Personnel who will be 
taking your blood are experienced in phlebotomy (procedures to take blood samples) and are 
qualified to do so under guidelines established by the Texas Department of Health and Human 
Services.  This will take about 5 minutes.  You will then have your total body water determined 
using a bioelectrical impedance analyzer (BIA).  The BIA analysis will involve lying down on your 
back on a table and having two small electrodes placed on your right hand and your right foot.  
The analyzer wires will be attached and a small and safe current (500 micro-amps at a frequency 
of 5- kHz) will pass through your body so that the amount of water can be measured. This 
analyzer is commercially available and has been used in the health care/fitness industry as a 
means to assess body composition and body water for over 20 years. The use of this device has 
been approved by the Food and Drug Administration (FDA) to assess total body water and the 
current to be used has been deemed safe.  Your body composition and bone density will then be 
determined by using a Discovery W dual energy x-ray absorptiometer (DEXA). This will involve 
lying down on your back on the DEXA exam table in a pair of shorts or a gown for about 6 
minutes.  A low dose of radiation will scan your entire body to determine the amount of fat weight, 
muscle weight, and bone weight. You will be exposed to an x-ray dose that is similar to the 
amount of natural background radiation a person would receive in one month while living in 
College Station.  After this test, you will have resting blood pressure determined using a blood 
pressure cuff and stethoscope and heart rate determined by taking your pulse.  You will then 
perform a one repetition maximum (1RM) test on the bench press using standard procedures.  
This will involve warming up and performing successive one repetition lifts on the bench press 
until you determine your 1 RM.  You will then rest for 10-minutes and follow the same procedure in 
determining your 1 RM on the hip/leg sled.  These tests will take about 20 minutes to complete.  
You will then be asked to perform a 30-second Wingate anaerobic capacity test on a bike at your 
maximal intensity against a resistance of 7.5 J/kg/rev. You will receive a five minute warm up 
before you will be asked to pedal as fast as possible for the entire 30 seconds.  The same battery 
of tests will be performed at the post-study assessment 4 weeks into the study protocol.  All the 
assessments minus the exercise tests will also be performed at 1 week into the study protocol.  
Each testing session will take between 1.5 and 3 hours to complete.  In the event of an emergency 
during an exercise test proper emergency response protocols (calling 9-911 for serious injury or a 
medical emergency, calling Biosafety/EHS for cleanup assistance or spill team response, calling 
UPD for incidents in public areas, retrieving AED located in the lab, performing CPR or other First 
Aid techniques, etc.) will be followed by the Exercise & Sport Nutrition Laboratory (ESNL) Staff 
depending on the severity of the emergency.         
 
After baseline testing, you will be matched into one of three groups according to age, body weight, 
and training status/experience and asked to ingest supplements containing CM (Creapure 
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AlzChem, Trostberg, Germany) or KA (Kre-alkalyn, Billings, MT).  The initial 7 day loading dose 
will be 20 grams of CM, the purported equivalent dose of KA, and the manufacturers 
recommended dose.  After the 7 day loading period you will be asked to ingest one 5 grams dose 
per day of CM, the purported equivalent dose of KA, or the manufacturers recommended dose of 
KA for 21 days.  You will be asked to ingest the supplements at 8:00 a.m., 12:00 p.m., 4:00 p.m. 
and 8:00 p.m. during the loading phase and at 8:00 a.m. during the maintenance phase.  The 
supplements will be provided with similar texture, taste, and appearance and placed in generic 
single serving packets for double-blind administration.  Your compliance will be monitored by 
asking that you return empty containers of the supplement at the end of each testing session.  In 
addition your compliance will be verified by administering and collecting daily questionnaires.  
After completing the compliance procedures you will be given the required supplement dosage for 
the next day.  Everyone, regardless of group assignment, will be asked to keep a food record and 
food frequency log to monitor dietary compliance.     
 
Please do your best to:  1) follow the instructions outline by the investigators; 2) show up to all 
scheduled testing and training sessions; and 3) follow the diet prescribed and do not take any 
other nutritional supplements or performance enhancing aids during this study (i.e., 
vitamins/minerals, creatine, HMB, androstenedione, DHEA, etc).  In addition, please do not take 
any non-medically prescribed medications and report any medication that is prescribed for you to 
take during this study.  If you take any other nutritional supplements or medications during the 
course of the study that may affect vitamin/mineral status, body composition, or strength you may 
be removed from the study. 
 
Table 1.   Overview of Research Design  
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What are the risks involved in this study? 
The risks associated with this study are:  You will be exposed to a low level of radiation during the 
DEXA body composition tests, which is similar to the amount of natural background radiation you 
would receive in one month while living in College Station.  In addition, a very low level of 
electrical current will be passed through your body using a bioelectrical impedance analyzer (BIA). 
This analyzer is commercially available and has been used in the health care/fitness industry as a 
means to assess body composition and body water for over 20 years.  The BIA and DEXA 
analyzers have been shown to be safe methods of assessing body composition and total body 
water and are approved by the FDA.  You will donate about 4 teaspoons (20 milliliters) of venous 
blood three (3) times during the study using standard phlebotomy procedures.   This procedure 
may cause a small amount of pain when the needle is inserted into the vein as well as some 
Familiarization 
and Entry 
 
Baseline 
Day 0 (T1) 
 
Loading Phase  
Day 7 (T2) 
Training Phase 
Day 28 (T3) 
 
Familiarization session 
 
Informed Consent Form 
 
Demographic Form 
 
Health History Form 
 
Exercise History Form 
 
4-day Dietary History 
 
Distribute Eight 3 L 
Urine Containers  
 
General Exam to 
Determine 
Qualifications to 
Participate in Study 
 
Determination of 
Height and Body 
Weight 
 
Randomization Into 3 
Groups (CM, KA 
recommended, KA 
equivalent)  
 
Instructions for 
Supplementation  
 
  
Baseline Muscle Biopsy  
 
Baseline Fasting Blood 
Sample 
 
Turn in Final Urine 
Container 
 
Body Weight  
 
Body Water (BIA) 
 
DEXA Body 
Composition 
 
1 RM Bench Press 
 
1 RM Leg Press 
 
Wingate Anaerobic 
Capacity Test 
 
Loading Phase of 
Supplementation 
Begins 
 
Maintain Training Log 
 
 
 
 
4-Day Diet History 
 
Submit Training Log 
 
Muscle Biopsy  
 
Fasting Blood Sample 
 
Body Weight  
 
Body Water (BIA) 
 
DEXA Body 
Composition 
 
Wingate Anaerobic 
Capacity Test 
 
Low-Dose Maintenance 
Phase of  
Supplementation 
Begins 
 
 
 
4-Day Diet History 
 
Submit Training Log 
 
Muscle Biopsy  
 
Fasting Blood Sample 
 
Body Weight  
 
Body Water (BIA) 
 
DEXA Body 
Composition 
 
1 RM Bench Press 
 
1 RM Leg Press 
 
Wingate Anaerobic 
Capacity Test 
 
 101 
 
 
bleeding and bruising. You may also experience some dizziness, nausea, and/or faint if you are 
unaccustomed to having blood drawn.  The biopsy procedure carries the risk of soreness (100%), 
infection (<1%), and permanent numbness (<<1%).  The exercise tests that will be performed may 
cause symptoms of fatigue, shortness of breath, and/or muscular fatigue/discomfort.  The exercise 
tests may also cause short-term muscle soreness and moderate fatigue for several days following 
the tests.  You may also experience muscle strains/pulls during the exercise testing and/or training 
program.  However, exercise sessions will be conducted by trained personnel and monitored to 
ensure you follow appropriate exercise guidelines.  The likelihood of any of these occurring is slim.   
 
What are the possible benefits of this study? 
The possible benefit you may receive from participation in this study is increased physical fitness 
and improvements in body composition.  You may also gain insight about your health and fitness 
status from the assessments that will be performed.      
 
Do I have to participate? 
No.  Your participation is voluntary.  You may decide not to participate or to withdraw at any time 
without your current or future relations with Texas A&M University being affected.   
 
Will I be compensated? 
You will receive $150 ($50 for each testing session) upon completion of the study.  Disbursement 
will occur upon completion of all sessions and after all study related materials (food logs, training 
logs, etc.) are turned in.  Those forced to terminate the study prior to completion will be 
compensated on a pro-rated basis depending on the total number of sessions completed.   
 
Who will know about my participation in this research study? 
This study is confidential.  The records of this study will be kept private.  No identifiers linking you 
to this study will be included in any sort of report that might be published.  Research records will 
be stored securely and only Mr. Christopher Rasmussen and Dr. Richard Kreider will have access 
to the records.   
 
Whom do I contact with questions about the research?  
If you have questions regarding this study, you may contact Dr. Richard Kreider, 945-1333, 
rkreider@hlkn.tamu.edu or Mr. Christopher Rasmussen, 458-1741, crasmussen@hlkn.tamu.edu.  
 
Whom do I contact about my rights as a research participant?   
This research study has been reviewed by the Human Subjects’ Protection Program and/or the 
Institutional Review Board at Texas A&M University.  For research-related problems or questions 
regarding your rights as a research participant, you can contact these offices at (979)458-4067 or 
irb@tamu.edu. 
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Signature   
Please be sure you have read the above information, asked questions and received answers to 
your satisfaction.  You will be given a copy of the consent form for your records.  By signing this 
document, you consent to participate in this study. 
 
Signature of Participant: ___________________________________________    Date: 
______________ 
 
Printed Name: 
________________________________________________________________________   
 
Signature of Person Obtaining Consent: _____________________________    Date: 
______________ 
 
Printed Name: 
________________________________________________________________________ 
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 APPENDIX B 
 
PERSONAL INFORMATION WORKSHEET 
Texas A&M University 
EXERCISE & SPORT NUTRITION LABORATORY 
 Personal Information 
 
Name:  
__________________________________________________________________________
                                                                                                                                                 
 
Address:  
____________________________________________________________________________ 
                                                                                                                                                  
 
City:                       State:                Zip Code              SS# ___________________ 
 
Home Phone:     (      ) ____________________  Work Phone: (      ) ____________________            
                    
 
Beeper:  (      ) ____________________  Cell Phone: (      ) ____________________
  
 
Fax:  (      )                               E-mail address: _________________________ 
 
Birth date:            /            /              Age:  ______  Height:  __________  Weight:  __________              
   Exercise History/Activity Questionnaire 
 
1. Describe your typical occupational activities. 
 
 
2. Describe your typical recreational activities 
 
 
3. Describe any exercise training that you routinely participate.  
 
 
4. How many days per week do you exercise/participate in these activities? 
 
 
5. How many hours per week do you train? 
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6. How long (years/months) have you been consistently training?   
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APPENDIX C 
MEDICAL HISTORY QUESTIONNAIRE 
 
Texas A&M UNIVERSITY 
EXERCISE & SPORT NUTRITION LABORATORY 
 
Medical History Inventory 
 
Directions.  The purpose of this questionnaire is to enable the staff of the Exercise and 
Sport Sciences Laboratory to evaluate your health and fitness status.  Please answer the 
following questions to the best of your knowledge.  All information given is 
CONFIDENTIAL as described in the Informed Consent Statement. 
  
Name:______________________________ Age _____Date of Birth_______________ 
 
Name and Address of Your 
Physician:_____________________________________________________ 
 
MEDICAL HISTORY 
 
Do you have or have you ever had any of the following conditions? (Please write the 
date when you had the condition in the blank). 
 
____Heart murmur, clicks, or other cardiac findings?
____Asthma/breathingdifficulty?  
____ Frequent extra, skipped, or rapid heartbeats?  ____Bronchitis/Chest Cold? 
____Chest Pain of Angina (with or without exertion)? ____Cancer, Melanoma, or  
        Suspected Skin Lesions? 
____High cholesterol?    ____Stroke or Blood Clots? 
____Diagnosed high blood pressure?   ____Emphysema/lung disease? 
____Heart attack or any cardiac surgery?  ____Epilepsy/seizures? 
____Leg cramps (during exercise)?   ____Rheumatic fever? 
 ____Chronic swollen ankles?    ____Scarlet fever? 
____Varicose veins?     ____Ulcers? 
____Frequent dizziness/fainting?   ____Pneumonia? 
____Muscle or joint problems?   ____Anemias? 
____High blood sugar/diabetes?   ____Liver or kidney disease? 
____Thyroid Disease?    ____Autoimmune disease? 
____Low testosterone/hypogonadism?  ____Nerve disease? 
____Glaucoma?     ____Psychological Disorders? 
____Bleeding Disorders 
 
 
Do you have or have you been diagnosed with any other medical condition not listed?  
_______________________________________________________________________ 
_______________________________________________________________________ 
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Please provide any additional comments/explanations of your current or past medical 
history.  
_______________________________________________________________________ 
_______________________________________________________________________ 
 
Please list any recent surgery (i.e., type, dates etc.).  
_______________________________________________________________________ 
_______________________________________________________________________ 
 
List all prescribed/non-prescription medications and nutritional supplements you have 
taken in the last 3 months.  
_______________________________________________________________________
_______________________________________________________________________ 
 
What was the date of your last complete medical exam?   
_______________________________________________________________________
______________________________ 
 
Do you know of any medical problem that might make it dangerous or unwise for you to 
participate in this study?  (including strength and maximal exercise tests)  ____ If yes, 
please explain: _________________ 
_______________________________________________________________________
______________________________________________________________________ 
 
Recommendation for Participation (for ESNL use only):   
 
____ No exclusion criteria presented. Subject is cleared to participate in the study. 
____ Exclusion criteria is/are present. Subject is not cleared to participate in the study. 
 
Signed: ___________________________________ Date: ________________________ 
